Novel Polypeptides

Secondary mutations in bispecific antibodies address the challenge of immunogenicity and purity issues, enhancing their therapeutic suitability by reducing immunogenicity and improving manufacturing efficiency.

JP2024542142APending Publication Date: 2024-11-13ALLIGATOR BIOSCI
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
JP2024526902
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2022-09-02
Filing Date
2022-11-04
Publication Date
2024-11-13

AI Technical Summary

Technical Problem

Existing bispecific antibodies are challenging to produce in good yield and purity while avoiding mutations that increase immunogenicity, which hampers their therapeutic suitability.

Method used

Introduction of secondary mutations, referred to as 'optimized RUBY mutations', in bispecific antibodies to reduce immunogenicity and improve purity during manufacturing, building upon existing primary mutations that may have already shown good immunogenicity profiles and ease of manufacture.

Benefits of technology

The optimized mutations further enhance the properties of bispecific antibodies, reducing immunogenicity risks and improving manufacturing purity, making them more suitable for therapeutic use.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024542142000001_ABST
    Figure 2024542142000001_ABST
Patent Text Reader

Abstract

The present invention relates to polypeptides (particularly bispecific antibodies) that contain novel mutations that reduce immunogenicity and / or improve purity during manufacture.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to polypeptides (particularly bispecific antibodies) that contain novel mutations that reduce immunogenicity and / or improve purity during manufacture. [Background technology]

[0002] Cancer is the leading cause of premature death in developed countries. The goal of cancer immunotherapy is to mount an effective immune response against tumor cells. This can be achieved, for example, by breaking tolerance to tumor antigens, enhancing antitumor immune responses, and stimulating local cytokine responses at the tumor site. The main effector cells of long-lasting antitumor immune responses are activated tumor-specific effector T cells. Strong expansion of activated effector T cells can redirect the immune response against tumors. In this context, regulatory T cells (Tregs) play a role in inhibiting antitumor immunity. Thus, depleting, inhibiting, reversing, or inactivating Tregs can provide antitumor effects and reverse immune suppression in the tumor microenvironment. Furthermore, incomplete activation of effector T cells, for example, by dendritic cells, can cause T cell anergy, which results in an insufficient antitumor response, whereas proper induction by dendritic cells can result in strong expansion of activated effector T cells to redirect the immune response against tumors. In addition, natural killer (NK) cells play an important role in tumor immunology by attacking tumor cells with downregulated human leukocyte antigen (HLA) expression and by inducing antibody-dependent cellular cytotoxicity (ADCC). Therefore, stimulating NK cells can also reduce tumor growth.

[0003] Therapeutic polypeptides (especially bispecific antibodies) are useful in cancer treatment because they allow for dual targeting of cells. For example, bispecific antibodies can activate host immune cells in the vicinity of tumor cells, and thus are an alternative to existing monospecific drugs that only target one antigen.

[0004] Bispecific antibodies are more difficult to generate compared to monoclonal antibodies. Many different formats have been devised, all with different advantages and limitations.

[0005] The challenge for the development of bispecific antibodies is to design structures and amino acid sequences that are practical to produce in good yield and purity, while avoiding any modifications (especially mutations) that lead to increased immunogenicity that would reduce their suitability for therapeutic use.

[0006] Against this background, the present inventors have surprisingly identified polypeptide mutations that reduce immunogenicity and / or improve purity during manufacturing. Summary of the Invention

[0007] The following invention provides new mutations in polypeptides, particularly and preferably bispecific antibodies of the RUBY format structure shown in FIG. 11. These mutations ("secondary mutations" as described herein) further reduce the immunogenicity of other mutations introduced into the antibody ("primary mutations" as described herein) and / or improve the purity and ease of manufacture of the polypeptide ("improved purity mutations" as described herein).

[0008] It should be noted that the new mutations described herein further significantly improve the properties of the polypeptides to which they are applied, which may themselves already have a good immunogenicity profile and ease of manufacture. For example, the exemplary polypeptides to which the new mutations are applied have already been available in large numbers for some time and have been safe in the clinic. The new mutations described herein improve their excellent previous properties. On this basis, these new mutations may be referred to as "optimized". DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0009] In a first aspect, the present invention provides a polypeptide having specificity for an antigen, the polypeptide comprising a heavy chain region and a light chain region, i. the polypeptide comprises one or more primary mutations to facilitate association of the heavy and light chain regions, which mutations increase the predicted risk of inducing an immunogenic response and / or increase the immunogenicity of the polypeptide; ii. The polypeptide comprises one or more secondary mutations to reduce or avoid the predicted risk of inducing an immunogenic response and / or to reduce or avoid the predicted risk immunogenicity caused by the one or more primary mutations.

[0010] The term "polypeptide" is used herein in its broadest sense to refer to a compound of two or more subunit amino acids, amino acid analogs, or other peptidomimetics. Thus, the term "polypeptide" includes short peptide sequences, as well as longer polypeptides and proteins. As used herein, the term "amino acid" refers to any natural and / or unnatural or synthetic amino acid, including both D or L optical isomers, and amino acid analogs and peptidomimetics.

[0011] In a preferred embodiment, the polypeptide is an antibody.

[0012] In a further preferred embodiment, the polypeptide is a bispecific polypeptide, more preferably a bispecific antibody. In an alternative embodiment, the polypeptide is a monospecific polypeptide.

[0013] As used herein, the term "antibody" or "antibodies" refers to a molecule that contains an antigen-binding site, e.g., immunoglobulin molecules and immunologically active fragments of immunoglobulin molecules that contain an antigen-binding site. Immunoglobulin molecules can be of any type (e.g., IgG, IgE, IgM, IgD, IgA, and IgY), class (e.g., IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2), or subclass of immunoglobulin molecule. Antibodies include, but are not limited to, synthetic antibodies, monoclonal antibodies, single domain antibodies, single chain antibodies, recombinantly produced antibodies, multispecific antibodies (including bispecific antibodies), human antibodies, humanized antibodies, chimeric antibodies, intrabodies, scFvs (including, e.g., monospecific and bispecific), Fab fragments, F(ab') fragments, disulfide-linked Fvs (sdFvs), anti-idiotypic (anti-Id) antibodies, and epitope-binding fragments of any of the above.

[0014] The term "bispecific" as used herein means that a polypeptide is capable of specifically binding to two different target entities. A bispecific polypeptide (e.g., an antibody) that targets two targets may induce specific activation of the immune system in the location where both targets are overexpressed.

[0015] The term "antibody with specificity for" refers to an antibody that is configured to direct its binding specificity(s) to a particular target / marker / epitope / antigen, i.e., an antibody that immunospecifically binds to the target / marker / epitope / antigen. Also, the terms "selective," "directed," "binds," "for," or "directed against" a particular target / marker / epitope / antigen may be used with the same definition as "having specificity." A bispecific antibody that has specificity for two different targets / markers / epitopes / antigens immunospecifically binds to both targets / markers / epitopes / antigens. When an antibody is directed against a particular target antigen, such as CD40, it is believed that the antibody may be directed against any suitable epitope present on the target antigen structure.

[0016] Those skilled in the art of immunology will understand and appreciate the concept of "promoting association of heavy and light chain regions", including that the primary mutation prevents the heavy and light chain regions from incorrectly combining, i.e., the mutation prevents the formation of manufacturing by-products. Alternatively, or in addition, the primary mutation may prevent the heavy and light chain regions from self-aggregating, i.e., the mutation prevents the formation of aggregates. Those skilled in the art will appreciate that in one embodiment, the primary mutation may prevent the formation of aggregates and / or by-products by creating steric hindrance and / or charge incompatibility. These terms are discussed in more detail below.

[0017] The term "immunogenicity," as will be understood by those skilled in the art of immunology, includes the characteristic of a polypeptide to stimulate an unwanted immune response directed against the polypeptide in an individual to which the polypeptide is administered.

[0018] In a preferred embodiment, increased immunogenicity is characterized as a higher predicted immunogenicity risk compared to the predicted immunogenicity risk of a primary mutation control polypeptide, and / or a higher immunogenicity compared to the immunogenicity of a primary mutation control polypeptide, preferably the primary mutation control polypeptide does not contain one or more primary mutations.

[0019] In certain embodiments, a primary mutation control polypeptide comprises or consists of an amino acid sequence that is the same as the polypeptide before one or more primary mutations are introduced.

[0020] In a preferred embodiment, reduced immunogenicity is characterized as a lower predicted immunogenicity risk compared to the predicted immunogenicity risk of a first secondary mutation control polypeptide, and / or a lower immunogenicity compared to the immunogenicity of a first secondary mutation control polypeptide, preferably the first secondary mutation control polypeptide comprises one or more primary mutations but does not comprise one or more secondary mutations.

[0021] In certain embodiments, the first secondary mutation control polypeptide comprises or consists of an amino acid sequence that is the same as the polypeptide containing one or more of the primary mutations before the one or more secondary mutations are introduced.

[0022] In a preferred embodiment, avoidance of immunogenicity is characterized as a similar or the same predicted immunogenicity risk compared to the predicted immunogenicity risk of a second, secondary mutant control polypeptide, and / or a similar or the same predicted immunogenicity compared to the immunogenicity of a second, secondary mutant control polypeptide, preferably the second, secondary mutant control polypeptide does not contain one or more primary mutations or one or more secondary mutations.

[0023] In certain embodiments, the second, secondary mutation control polypeptide comprises or consists of an amino acid sequence that is the same as the polypeptide before one or more primary mutations are introduced and before one or more secondary mutations are introduced.

[0024] As illustrated in the examples (particularly Example 1), one way to predict or identify the immunogenicity of a polypeptide is to predict in silico whether its amino acid sequence will bind to molecules and / or receptors in an individual that will result in an undesired immune response, such as considering whether it will bind to the major histocompatibility complex II (MHCII). This can be done using, among other techniques, the AbEpiAnalyzer tool (EIR Sciences). How to make such predictions within the above-mentioned embodiments, such as comparing the amino acid sequence of a polypeptide of the invention to a first mutation control polypeptide, a first secondary mutation control polypeptide, and / or a second secondary mutation control polypeptide, will be understood by those skilled in the art of immunology and / or computational biology.

[0025] It will also be appreciated that in vivo and / or in vitro experiments regarding the immunogenicity of the polypeptides of the invention (including in conjunction with the control polypeptides discussed herein) can also be carried out, for example using suitable model organisms.

[0026] In one embodiment, the immunogenicity is antigen presenting cell (APC) immunogenicity and / or T cell dependent immunogenicity.

[0027] The terms antigen-presenting cells (APCs) and T cells will be known to those skilled in the art of immunology. In particular, with respect to APCs, these are cells that process and present antigens within the context of MHC. APCs can then present these antigens to other immune cells, such as T cells.

[0028] In a particular embodiment, the APC is one or more APCs selected from the list comprising dendritic cells, macrophages, or B cells, preferably dendritic cells.

[0029] In a preferred embodiment, the secondary mutation reduces or avoids polypeptide binding to MHC class II and / or the T cell receptor (TCR), preferably MHC class II.

[0030] The concept of a mutation that reduces or prevents the binding of a polypeptide to MHC class II and / or TCR will be recognized and understood by those skilled in the art of immunology. "Reducing polypeptide binding" includes that the affinity of the polypeptide with secondary mutations of MHC class II and / or TCR is lower than that of a polypeptide without those secondary mutations (such as the first secondary mutation control polypeptide described above). "Avoiding polypeptide binding" includes that there is no detectable binding between a polypeptide with secondary mutations and MHC class II and / or TCR. An exemplary method for measuring binding affinity is a competitive immunoassay (such as that described in Wang et al., 2008 PLoS Comput Biol. 4(4): e1000048) or Octet, as described in the Examples.

[0031] In a second aspect, the present invention provides a polypeptide having specificity for an antigen, wherein the polypeptide comprises a heavy chain variable domain (VH) comprising a Protein A binding site, wherein the VH domain comprises a mutation that reduces or avoids binding of Protein A to the Protein A binding site.

[0032] As known by those skilled in the art of immunology, Protein A was originally found in Staphylococcus aureus and has a high affinity for several mammalian proteins, including IgG (such as VH domains). Due to its affinity for IgG, Protein A is often used to selectively isolate polypeptides during purification. While this is a useful tool, when a polypeptide is complex, particularly when the polypeptide is made of multiple polypeptide chains such as the bispecific antibodies described herein, Protein A sites in the polypeptide may result in co-purification of the complete polypeptide of interest with undesired misfolded or unbound component polypeptide chains. As will be appreciated, this co-purification may result in contamination with undesired polypeptides. Thus, the inventors have identified that it may be desirable to mutate Protein A binding sites, particularly in regions of the polypeptide that are prone to forming undesired polypeptides during the manufacturing process. The inventors have surprisingly found that by mutating Protein A binding sites in the VH domain, the purity of the polypeptide of interest during the manufacturing process may be improved. The Protein A binding site mutations described herein are "optimized RUBY" mutations, which may also be referred to as "improved purity" mutations.

[0033] The concept of a mutation causing a reduction or avoidance of binding of protein A to the protein A binding site will be recognized and understood by those skilled in the art of immunology. "Reducing binding of protein A to the protein A binding site" includes that the affinity of protein A with the mutation to the protein A binding site is lower than the affinity of protein A without the mutation to the protein A binding site and / or that the mutation reduces the affinity of protein A to such an extent that it can no longer bind (and / or co-purify) by a protein A specific method during antibody production. "Avoiding binding of protein A to the protein A binding site" includes that there is no detectable binding between protein A and the protein binding site with the mutation. An exemplary method for measuring binding affinity is Octet, as described in the Examples.

[0034] In certain embodiments, the mutation that reduces or avoids binding of protein A to the protein A binding site is one or more mutations that reduce or avoid binding of protein A to the protein A binding site.

[0035] In one embodiment of the second aspect of the invention, the VH is derived from the IGHV3 germline gene family.

[0036] VHs derived from the IGHV3 germline gene family are particularly susceptible to mutations that reduce or avert Protein A binding, as they have a Protein A binding site with the Protein A binding domain constituting the site identified in framework regions 1, 3 and the conserved portion of CDRH2. This is discussed further in Bach, Lewis et al. 2015 J Chromatogr A.; 1409:60-9, Potter et al. 1996, J Immunol.; 157(7):2982-8. PMID:8816406, and Potter et al 1997, Int Rev Immunol.; 14(4):291-308. doi:10.3109 / 08830189709116521. PMID:9186782.

[0037] In one embodiment, the mutations to the Protein A binding site are in one or more of the framework 1 region of the VH derived from the IGHV3 germline gene family, the framework 2 region of the VH derived from the IGHV3 germline gene family, and the CDRH2 of the VH derived from the IGHV3 germline gene family, preferably the CDRH2 of the VH derived from the IGHV3 germline gene family.

[0038] An exemplary IGHV3 germline gene family member is IGHV3-23*01, which has the following sequence: [ka]

[0039] In a preferred embodiment, the mutation to the Protein A binding site is to the last amino acid (ie, the C-terminal amino acid) of CDRH2 of a VH derived from the IGHV3 germline gene family.

[0040] It is included that the mutations of the first aspect of the invention can be combined with mutations of the second aspect of the invention in the same polypeptide. Such potential combinations of the mutations discussed herein are disclosed below.

[0041] In a preferred embodiment of the first and second aspects, the polypeptide is a bispecific antibody, (a) an immunoglobulin molecule having specificity for a first antigen, the immunoglobulin molecule comprising a first heavy chain region and a first light chain region; (b) at least one Fab fragment having specificity for a second antigen, the Fab fragment comprising a second heavy chain region and a second light chain region; a second light chain region is fused to the C-terminus of the first heavy chain region; The one or more primary mutations promote association of the first heavy chain region with the first light chain region and / or promote association of the second heavy chain region with the second light chain region. This particular embodiment includes a polypeptide having a RUBY format structure, as generally shown in Figure 11.

[0042] Thus, it will be understood by those skilled in the art that the term "immunoglobulin", as defined above, includes immunoglobulin molecules and immunologically active fragments of immunoglobulin molecules that contain an antigen-binding site.

[0043] As used herein, the term "antibody fragment" refers to a portion of an antibody, such as F(ab')2, F(ab)2, Fab', Fab, Fv, scFv, etc. Regardless of structure, an antibody fragment binds to the same antigen recognized by the intact antibody. For example, an anti-CD40 antibody fragment binds to CD40. The term "antibody fragment" also includes isolated fragments consisting of variable regions, such as an "Fv" fragment consisting of the variable regions of the heavy and light chains, and recombinant single-chain polypeptide molecules in which the light and heavy chain variable regions are linked by a peptide linker ("scFv protein"). As used herein, the term "antibody fragment" does not include portions of an antibody that do not have antigen-binding activity, such as an Fc fragment or a single amino acid residue.

[0044] "Fab fragment" includes a Fab fragment (containing the complete light chain and the variable and CH1 regions of the heavy chain) that is capable of binding to the same antigen recognized by an intact antibody. Fab fragment is a term known in the art and contains one constant domain and one variable domain from each of the heavy and light chains.

[0045] In one embodiment of the invention, one of binding domain B1 or binding domain B2 is an immunoglobulin molecule and one of binding domain B1 or binding domain B2 is a Fab fragment, which is fused via the light chain of the Fab fragment to the C-terminus of the heavy chain of the immunoglobulin.

[0046] For example, the polypeptide may have a format as shown in Figure 11. Such a format is referred to as the "RUBY™ format" (described in pending UK Patent Application No. 1820556.7 and PCT Application No. WO2020 / 127354). The "RUBY™ format" and "optimized RUBY™ format" antibodies described herein are particularly preferred for the bispecific polypeptides of the invention.

[0047] In one embodiment, one or more Fab fragments are linked to the C-terminus of the immunoglobulin via a linker.

[0048] In one embodiment of the invention, the bispecific polypeptide is tetravalent and capable of bivalently binding to each of two antigens.

[0049] In one embodiment, the bispecific polypeptide comprises an immunoglobulin arranged as an antibody with two arms, thus comprising two binding sites for a first antigen and two binding sites for a Fab fragment, each of which provides a binding site for a second antigen. Thus, there are two binding sites for a first antigen and two binding sites for a second antigen. The bispecific polypeptide of this embodiment comprises three polypeptide chains: (1) a chain H1 comprising an IgG heavy chain, a linker, and a Fab light chain, (2) a chain L1 which is an IgG light chain, and (3) a chain H2 which is an attached (combined) Fab heavy chain. In a preferred embodiment, the bispecific polypeptide may comprise six polypeptide chains: (a) two chains H1 comprising an IgG heavy chain, a linker, and a Fab light chain, (b) two chains L1 which are IgG light chains, and (c) two chains H2 which are attached (combined) Fab heavy chains. This structure can be used for both "RUBY™ format" and "optimized RUBY™ format" antibodies, the "H1", "H2" and "L1" chains of which are described below with reference to specific mutations.

[0050] In one embodiment, binding domain B1 is an immunoglobulin and binding domain B2 is a Fab. In an alternative embodiment, binding domain B1 is a Fab and binding domain B2 is an immunoglobulin.

[0051] Thus, the first heavy chain polypeptide is a polypeptide that comprises or consists of the heavy chain of a first antibody or antigen-binding fragment, and the first light chain polypeptide is a polypeptide that comprises or consists of the light chain of a first antibody or antigen-binding fragment.

[0052] Thus, the second heavy chain polypeptide is a polypeptide that comprises or consists of the heavy chain of a second antibody or antigen-binding fragment, and the second light chain polypeptide is a polypeptide that comprises or consists of the light chain of a second antibody or antigen-binding fragment.

[0053] The first antibody and the second antibody or antigen-binding fragment have specificity for a first antigen and a second antigen, respectively.

[0054] In one embodiment of a bispecific antibody of the invention, the immunoglobulin molecule comprises two copies of a first heavy chain polypeptide and / or two copies of a first light chain polypeptide.

[0055] Thus, in one embodiment, an immunoglobulin molecule comprises two heavy chain polypeptides and two corresponding light chain polypeptides. By "corresponding" it is meant that the heavy and light chains are assembled into an antibody format, i.e., the heavy chain associates with the light chain via the CH1 and CKappa or CLambda regions, and the VH and VL regions, and the heavy chain is also linked together via the CH2 and CH3 regions.

[0056] In one embodiment of a bispecific antibody of the invention, the immunoglobulin molecule comprises two copies of a first heavy chain polypeptide and / or two copies of a first light chain polypeptide.

[0057] Thus, in one embodiment, an immunoglobulin molecule comprises two heavy chain polypeptides and two corresponding light chain polypeptides. By "corresponding" it is meant that the heavy and light chains are assembled into an antibody format, i.e., the heavy chain associates with the light chain via the CH1 and CKappa or CLambda regions, and the VH and VL regions, and the heavy chain is also linked together via the CH2 and CH3 regions.

[0058] In one embodiment, the bispecific antibody comprises two Fab fragments according to (b), i.e., two Fab fragments with specificity for a second antigen, each of the Fab fragments comprising a second heavy chain polypeptide and a second light chain polypeptide.

[0059] Thus, in one embodiment, the bispecific antibody comprises: (a) an immunoglobulin molecule having specificity for a first antigen and comprising two heavy chain polypeptides and two light chain polypeptides; (b) two Fab fragments, the Fab fragments having specificity for a second antigen and comprising a second heavy chain polypeptide and a second light chain polypeptide.

[0060] Thus, in one embodiment, the bispecific antibody comprises: an immunoglobulin molecule comprising two copies of a first heavy chain polypeptide and two copies of a first light chain polypeptide; the bispecific antibody further comprises two Fab fragments having specificity for a second antigen, the Fab fragments each comprising a second heavy chain polypeptide and a second light chain polypeptide; a first Fab fragment is fused to the C-terminus of a first copy of a first heavy chain polypeptide via a light chain polypeptide of the Fab fragment; - A second Fab fragment is fused to the C-terminus of a second copy of the first heavy chain polypeptide via the light chain polypeptide of the Fab fragment.

[0061] In one embodiment of the bispecific antibody according to the first aspect of the invention, the immunoglobulin molecule comprises a human Fc region or a variant of said region, wherein the region is an IgG1, IgG2, IgG3, or IgG4 region, preferably an IgG1 or IgG4 region.

[0062] The constant (Fc) region of an antibody may mediate the binding of the immunoglobulin to host tissues or factors, including various cells of the immune system (e.g., effector cells) and the first component (C1q) of the classical complement system. The Fc region is preferably a human Fc region, or a variant of said region. The Fc region may be an IgG1, IgG2, IgG3, or IgG4 region, preferably an IgG1 or IgG4 region. The variant Fc region typically binds to an Fc receptor, such as Fc gamma R and / or neonatal Fc receptor (FcRn), with altered affinity and provides improved function and / or half-life of the polypeptide. The biological function and / or half-life may be either extended or decreased compared to the half-life of a polypeptide comprising a native Fc region. Examples of such biological functions that may be modulated by the presence of a variant Fc region include antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), complement-dependent cytotoxicity (CDC), and / or apoptosis.

[0063] One of skill in the art will appreciate that in one embodiment, the Fc region is a naturally occurring (i.e., wild-type) human Fc region. In an alternative embodiment, the Fc region is a non-naturally occurring (e.g., mutated) human Fc region.

[0064] In one embodiment, the Fc region of the immunoglobulin may have modified glycosylation, e.g., the Fc region may be afucosylated.

[0065] By "afucosylated," "defucosylated," or "nonfucosylated" antibody is meant an antibody that has no fucose sugar units attached to the Fc region thereof, or has a reduced content of fucose sugar units. Reduced content can be defined by the relative amount of fucose in the modified antibody compared to a fucosylated "wild type" antibody, e.g., fewer fucose sugar units per immunoglobulin molecule compared to a comparable antibody expressed in the absence of a mannosidase inhibitor and / or in the presence of GDP-6-deoxy-D-lyxo-4-hexulose reductase.

[0066] In one embodiment, one or more Fab fragments are linked to the C-terminus of the immunoglobulin via a linker. Thus, the linker can be a peptide linker that links the second light chain polypeptide to the first heavy chain polypeptide. In one embodiment, when there are two Fab fragments (and thus two second light chain polypeptides) and two first heavy chain polypeptides are also present in the immunoglobulin, each Fab fragment is linked to one of the first heavy chain polypeptides via a linker.

[0067] In one embodiment, the linker is a peptide having an amino acid sequence selected from the following: SGGGGSGGGGS (SEQ ID NO: 2), SGGGGSGGGGSAP (SEQ ID NO: 3), NFSQP (SEQ ID NO: 4), KRTVA (SEQ ID NO: 5), GGGSGGGGSGGGGS (SEQ ID NO: 6), or (SG)m, where m = 1 to 7.

[0068] Primary Mutation In one embodiment, the light chain region comprises a CKappa or CLambda domain and the primary mutation is at position 114 of the CKappa or CLambda (preferably CKappa) domain (according to the EU or Kabat numbering system) and / or the heavy chain region comprises a CH1 domain and the primary mutation is at position 187 of the CH1 domain (according to the EU numbering system). In a particular embodiment, the light chain region comprises a CKappa or CLambda domain and the primary mutation is at position 114 of the CKappa or CLambda (preferably CKappa) domain. In an alternative particular embodiment, the heavy chain region comprises a CH1 domain and the primary mutation is at position 187 of the CH1 domain. In a further embodiment, the primary mutation is at position 114 of the CKappa or CLambda (preferably CKappa) domain (according to the EU or Kabat numbering system) and at position 187 of the CH1 domain (according to the EU numbering system).

[0069] In a preferred embodiment, the primary mutation is at position X114A in the CKappa or CLambda (preferably CKappa) domain and / or at position X187E / D in the CH1 domain. In a particular embodiment, the primary mutation is X114A in the CKappa or CLambda (preferably CKappa) domain. In an alternative particular embodiment, the primary mutation is X187E / D in the CH1 domain. In a further embodiment, the primary mutation is X114A (according to the EU or Kabat numbering system) in the CKappa or CLambda (preferably CKappa) domain and X187E / D (according to the EU numbering system) in the CH1 domain. X stands for any amino acid.

[0070] In an alternative preferred embodiment, the primary mutation is T / S114X in the CKappa or CLambda (preferably CKappa) domain and / or T187X in the CH1 domain. In a particular embodiment, the primary mutation is T / S114X in the CKappa or CLambda (preferably CKappa) domain. In an alternative particular embodiment, the primary mutation is T187X in the CH1 domain. In a further embodiment, the primary mutation is T / S114X (according to the EU or Kabat numbering system) in the CKappa or CLambda (preferably CKappa) domain and T187X (according to the EU numbering system) in the CH1 domain. X refers to any amino acid.

[0071] The use of " / " in contexts where mutations are discussed is to illustrate alternative amino acids, for example, "X187E / D" indicates that E or D can be included at position 187 as an alternative to amino acid "X".

[0072] In a further preferred embodiment, the primary mutation is T / S114A in the CKappa or CLambda (preferably CKappa) domain and / or T187E / D in the CH1 domain. In a particular embodiment, the primary mutation is T / S114A in the CKappa or CLambda (preferably CKappa) domain. In an alternative particular embodiment, the primary mutation is T187E / D in the CH1 domain. In a further embodiment, the primary mutation is T / S114A in the CKappa or CLambda (preferably CKappa) domain (according to the EU or Kabat numbering system) and T187E / D in the CH1 domain (according to the EU numbering system).

[0073] In a preferred embodiment, the primary mutation at position 187 of the CH1 domain is in the "H1" chain as described herein and / or the "H2" chain as described herein, preferably the "H2" chain.

[0074] In a preferred embodiment, the primary mutation at position 114 of the CKappa or CLambda (preferably CKappa) domain is in the "H1" chain as described herein and / or the "L1" chain as described herein, preferably the "H1" chain. [Table 1-1] [Table 1-2] [Table 1-3] [Table 1-4] [Table 2-1] [Table 2-2]

[0075] In one embodiment the primary mutation at position 114 of the CKappa or CLambda (preferably CKappa) domain is at position X of an amino acid sequence selected from Table B.

[0076] In a particular embodiment, the primary mutation at position 114 of the CKappa or CLambda (preferably CKappa) domain is at position X of a 3-mer, 5-mer, 7-mer, 9-mer, 11-mer, 13-mer, 15-mer, 17-mer, 19-mer, 21-mer, or 23-mer amino acid sequence selected from Table B, centered at position X, such as the 9-mer sequence of this embodiment: [ka] (SEQ ID NO:51) is [ka] (SEQ ID NO: 75).

[0077] In a further embodiment, the primary mutation at position 114 of the CKappa or CLambda (preferably CKappa) domain is [ka] and having at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or at least 95% sequence identity to an amino acid sequence selected from Table B.

[0078] In a preferred embodiment, the primary mutation at position 114 of the CKappa domain is [ka] (SEQ ID NO:52), or [ka] (SEQ ID NO:56), or [ka] (SEQ ID NO:59) at position X.

[0079] In a further preferred embodiment, the primary mutation at position 114 of the CKappa domain is [ka] (SEQ ID NO: 285) at position X.

[0080] In a particularly preferred embodiment, the amino acid replacing the amino acid at position 114 of any of the amino acid sequences of Table B is A, as further explained above. [Table 3]

[0081] In one embodiment, the CH1 domain is from an Fc isotype selected from the list including: IgG1, IgG2, IgG3, and IgG4.

[0082] Most preferably, the CH1 domain is from IgG1. [Table 4]

[0083] In one embodiment the primary mutation at position 187 of the CH1 domain is at position X of an amino acid sequence selected from Table D.

[0084] In certain embodiments, the primary mutation at position 187 of the CH1 domain is at position X of a 3-mer, 5-mer, 7-mer, 9-mer, 11-mer, 13-mer, 15-mer, 17-mer, 19-mer, 21-mer, 23-mer, 25-mer, 27-mer, 29-mer, or 31-mer amino acid sequence selected from Table D, e.g., the sequence [ka] The 9mer of this embodiment in (SEQ ID NO: 80) is [ka] (Sequence number 86).

[0085] In a further embodiment, the primary mutation at position 187 of the CH1 domain is [ka] and having at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or at least 95% sequence identity to an amino acid sequence selected from Table D.

[0086] While the positioning of mutations in the amino acid sequences described herein refers to numerical values ​​(e.g., "the primary mutation at position 187 of the CH1 domain is at position X of the amino acid sequence AVLQSSGLYSLSSVVXVPSSSLGTQTYICNV (SEQ ID NO: 80)"), it will be understood that this is to allow cross-referencing between these particular embodiments and other embodiments in which those mutations are further discussed. Thus, it is also encompassed that mutations described within the disclosed amino acid sequences may be included in the context of that sequence, but not in the overall position designated by the associated number. Thus, by way of example, it is also included that the primary mutation can be at position X of the amino acid sequence AVLQSSGLYSLSSVVXVPSSSLGTQTYICNV (SEQ ID NO: 80) or GLYSLSSVVXVP (SEQ ID NO: 84) or VXV (SEQ ID NO: 85), whereby the primary mutation is at position 187 of the CH1 domain at position X of the amino acid sequence AVLQSSGLYSLSSVVXVPSSSLGTQTYICNV (SEQ ID NO: 80) or GLYSLSSVVXVP (SEQ ID NO: 84) or VXV (SEQ ID NO: 85).

[0087] Secondary Mutation The "secondary mutations" described herein may be referred to as "Optimized RUBY™" mutations, in particular "Mutation Set 2" (including "Set 2a" and / or "Set 2b").

[0088] While the "RUBY™ format" bispecific polypeptides have been designed for clinical use and are less immunogenic, the "optimized RUBY™ format" bispecific polypeptides having "secondary mutations" have been engineered to further reduce the risk of eliciting an immunogenic response against the bispecific polypeptide itself.

[0089] It will be understood by those skilled in the art that various combinations of these secondary mutations can be used in the polypeptides (preferably bispecific polypeptides) of the invention, as well as in combination with any of the primary mutations described above. Combinations of primary and secondary mutations used in the same polypeptide are described below. It is also understood that variations of these mutations described herein will function as part of the present invention. All mutations in the variable domains (VH or VL) are numbered according to the IMGT numbering system, all mutations in the constant C Appa light chain domains are numbered according to the EU or Kabat numbering system, all mutations in the constant C Lambda light chain domains are numbered according to the Kabat numbering system, and all mutations in the constant heavy chains are numbered according to the EU numbering system.

[0090] In one embodiment, the one or more secondary mutations are at one or more positions up to 8 amino acids upstream and / or downstream from the primary mutation in a sequence of contiguous amino acids.

[0091] In certain embodiments, the one or more secondary mutations are located in a sequence of contiguous amino acids (such as the amino acid sequence of Table B) at one or more positions up to 8 amino acids upstream and / or downstream from the primary mutation at position 114 of the CKappa or CLambda (preferably Ckappa) domain.

[0092] When the positioning of amino acids upstream of position 114 of the CKappa or CLambda domain is discussed, this may extend to the VL domain N-terminal to the CKappa or CLambda domain.

[0093] According to the EU or Kabat numbering system, the N-terminal boundary of the CKappa domain is at position 108, before which the adjacent amino acid, according to the IMGT numbering, is in the VL domain and is numbered at position 127. Thus, the numbering of positions between the CKappa domain and the VL domain is as follows (CKappa domain is underlined, VL is in bold -X indicates the amino acid and number at that position): [ka] - The boundaries of the domains in the following sequences of the present application are as follows: [ka] (SEQ ID NO: 36: in this sequence the CKappa domain is underlined and the VL is in bold).

[0094] According to the Kabat numbering system, the N-terminal boundary of the CLambda domain is at position 107A, before which the adjacent amino acid, according to the IMGT numbering, is in the VL domain and is numbered at position 127. Thus, the numbering of positions between the CLambda and VL domains is as follows (CLambda domains are underlined and VL are in bold -X indicates the amino acid and number at that position): [ka] - [ka] (SEQ ID NO: 41: in this sequence the CLambda domain is underlined and the VL is in bold).

[0095] Thus, in one embodiment, the one or more secondary mutations are in the region from position 126 of the VL domain to position 122 of the CKappa domain. In an alternative embodiment, the one or more secondary mutations are in the region from position 127 of the VL domain to position 123 of the CLambda domain.

[0096] In further particular embodiments, the one or more secondary mutations are located in a sequence of contiguous amino acids (such as an amino acid sequence selected from Table D) at one or more positions up to 8 amino acids upstream and / or downstream from the primary mutation at position 187 of the CH1 domain, for example, the one or more secondary mutations are in the region from positions 179 to 195 of the CH1 domain.

[0097] In one embodiment, the secondary mutations are one or more mutations at a position in the amino acid sequence selected from Table B, wherein the mutation is not at position X and X is the amino acid A, and / or the secondary mutations are one or more mutations at a position in the amino acid sequence selected from Table D, wherein the mutation is not at position X and X is the amino acid E or D.

[0098] In certain embodiments, the secondary mutations are one or more mutations at positions in a 3mer, 5mer, 7mer, 9mer, 11mer, 13mer, 15mer, 17mer, 19mer, 21mer, or 23mer amino acid sequence selected from Table B centered around position X, where the mutation is not at position X and X is the amino acid A.

[0099] In a further embodiment, the secondary mutation is [ka] and having at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or at least 95% sequence identity to an amino acid sequence selected from Table B, wherein the mutation is not at position X, and X is the amino acid A.

[0100] In certain embodiments, the secondary mutations are one or more mutations at a 3mer, 5mer, 7mer, 9mer, 11mer, 13mer, 15mer, 17mer, 19mer, 21mer, 23mer, 25mer, 27mer, 29mer, or 31mer amino acid sequence position selected from Table D centered around position X, where the mutation is not at position X and X is the amino acid E or D.

[0101] In a further embodiment, the secondary mutation is [ka] and having at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or at least 95% sequence identity to an amino acid sequence selected from Table D, and no mutation is at position X, where X is amino acid E or D.

[0102] In one embodiment, the secondary mutations are [ka] (SEQ ID NO: 87), where position 9 is a primary mutation; [ka] is part of the VL domain, [ka] is part of the CKappa domain. In a preferred embodiment, the secondary mutation is [ka] (SEQ ID NO: 88), where X is any amino acid, and where position 9 is a primary mutation; [ka] is part of the VL domain, [ka] is part of the CKappa domain. Positions 1, 4, and 6 in this embodiment correspond to positions 126 of the VL domain and positions 109 and 111 of the CKappa domain of the embodiments herein. Longer versions of the amino acid sequences of this embodiment are set out in Table B, and those longer sequences containing the secondary mutations set out in this embodiment will be understood by those skilled in the art.

[0103] In an alternative embodiment, the secondary mutations are [ka] (SEQ ID NO: 89), where X is any amino acid, where position 9 is a primary mutation, and where L is part of a VL domain; [ka] is part of the CLambda domain. In a further alternative embodiment, the secondary mutation is [ka] (SEQ ID NO: 90), where X is any amino acid, where position 9 is a primary mutation, and where L is part of a VL domain; [ka] is part of the CLambda domain. Positions 4 and 6 of this embodiment correspond to positions 109 and 111 of the CLambda domain of the embodiments herein. Longer versions of the amino acid sequence of this embodiment are set out in Tables A and B, and those longer sequences containing the secondary mutations set out in this embodiment will be understood by those skilled in the art.

[0104] In one embodiment, the secondary mutation is [ka] (SEQ ID NO: 91), wherein X is any amino acid, and position 8 is a primary mutation; [ka] (SEQ ID NO: 92), where X is any amino acid, position 8 is a primary mutation, YSLSSVVEV (SEQ ID NO: 93) in the CH1 domain, where position 8 is a primary mutation or YSLSSVVEV (SEQ ID NO: 93) in the CH1 domain, where position 8 is a primary mutation, preferably positions 1 and 4, more preferably position 4. Positions 1, 4, 6, and 9 in this embodiment correspond to positions 180, 183, 185, and 188 in the following embodiment. Longer versions of the amino acid sequence of this embodiment are set out in Tables C and D, and those longer sequences containing the secondary mutations set out in this embodiment will be understood by those skilled in the art.

[0105] As discussed further below and in the Examples, the inventors have surprisingly determined that the relative position of the secondary mutation(s) to the primary mutation may be relevant to reducing the immunogenicity of the primary mutation, as the relative positions of the primary and secondary mutations may be important for altering the binding properties of the polypeptide to receptors that cause immunogenicity, such as MHC class II.

[0106] In one embodiment, the heavy chain region comprises a CH1 domain and the secondary mutation is at positions 180, 183, and / or 188, preferably 180 or 183, more preferably 183, of the CH1 domain (according to the EU numbering system).

[0107] In one embodiment, the light chain region comprises a CKappa or Clambda (preferably CKappa) domain and the secondary mutation is at position 111 and / or 109 of the CKappa or Clambda (preferably CKappa) domain.

[0108] In one embodiment, the light chain region comprises a VL domain and the secondary mutation is at position 126 of the VL domain.

[0109] In certain embodiments, the secondary mutations are at one or more of the following positions in the CKappa or CLambda (preferably CKappa) domain: positions 111 and 109 (according to the EU or Kabat numbering system) of the VL domain, and position 126 (according to the IMGT numbering system).

[0110] In one embodiment of the invention, the secondary mutation is at a position selected from the group consisting of: (a) one or more of the following positions in the CH1 domain: positions 180, 183, and 188, preferably position 180 (according to the EU numbering system); and / or (b) one or more of the following positions in the CKappa or CLambda (preferably CKappa) domain: positions 111 and 109 (according to the EU or Kabat numbering system); and / or (c) position 126 of the VL domain (according to the IMGT numbering system).

[0111] In certain embodiments, the secondary mutations are at two or more of the following positions: position 180 of the CH1 domain, position 183 of the CH1 domain, position 188 of the CH1 domain, position 111 of the CKappa or CLambda (preferably CKappa) domain, position 109 of the CKappa or CLambda (preferably CKappa) domain, and position 126 of the VL domain, such as three or more, four or more, five or more, or all six of these positions.

[0112] In one embodiment of the invention, the secondary mutation is at a position selected from the group consisting of: (a) one or more of the following positions in the CH1 domain: Y180, S183, and V188, preferably Y180 (according to the EU numbering system); and / or (b) one or more of the following positions in the CKappa domain: A111 and T109, or one or more of the following positions in the CLambda domain: A111 and P109 (according to the EU or Kabat numbering system); and / or (c) position I126 of the VL domain (according to the IMGT numbering system).

[0113] In certain embodiments, the secondary mutation is at one or more of the following positions in the CH1 domain: Y180, S183, and V188, preferably Y180 or S183, more preferably S183 (according to the EU numbering system).

[0114] In certain embodiments, the secondary mutations are at one or more of the following positions in the CKappa domain: A111 and T109 (according to the EU or Kabat numbering system) and / or at position I126 in the VL (according to the IMGT numbering system). In certain alternative embodiments, the secondary mutations are at one or more of the following positions in the CLambda domain: A111 and P109 (according to the Kabat numbering system).

[0115] In one embodiment of the invention, the secondary mutation is selected from the group consisting of: (a) one or more of the following mutations in the CH1 domain: Y180X, S183X, and V188X, preferably Y180X (according to the EU numbering system); and / or (b) one or more of the following mutations in the CKappa domain: A111X and T109X, or one or more of the following positions in the CLambda domain: A111X and P109X (according to the EU or Kabat numbering system); and / or (c) I126X (according to the IMGT numbering system) in the VL domain. *X stands for any amino acid

[0116] In certain embodiments, the secondary mutation is one or more of the following mutations in the CH1 domain: Y180X, S183X, and V188X, preferably Y180X or S183X, more preferably S183X (according to the EU numbering system). *X stands for any amino acid

[0117] In certain embodiments, the secondary mutation is one or more of the following mutations in the CKappa domain: A111X, and T109X (according to the EU or Kabat numbering system), and / or the mutation is I126X (according to the IMGT numbering system) in the VL domain. In certain alternative embodiments, the secondary mutation is one or more of the following positions in the CLambda domain: A111X, and P109X (according to the EU numbering system). *X stands for any amino acid

[0118] In one embodiment of the invention, the secondary mutation is selected from the group consisting of: (a) one or more of the following mutations in the CH1 domain: X180A / G / I / N / S / T / V / W, X183N / T, and X188G, preferably X180T (according to the EU numbering system); and / or (b) one or more of the following mutations in the CKappa or CLambda (preferably CKappa) domain: X111R / T / W / V and X109P, preferably X111V and X109P (according to the EU or Kabat numbering system); and / or (c) X126A / G / H / N / P / Q / S / T (according to the IMGT numbering system) of VL. *X stands for any amino acid

[0119] The use of " / " in contexts where mutations are discussed is to illustrate alternative amino acids, for example, "X180A / G / I / N / S / T / V / W" indicates that A or G or I or or S or T or V or W can be included at position 180 as alternatives to amino acid "X".

[0120] In certain embodiments, the secondary mutations are one or more of the following mutations in the CH1 domain: X180A / G / I / N / S / T / V / W, X183N / T, and X188G, preferably X180T or X183N / T, more preferably X183N / T (according to the EU numbering system). *X stands for any amino acid

[0121] In certain embodiments, the secondary mutations are one or more of the following mutations in the CKappa or CLambda (preferably CKappa) domain: X111R / T / W / V and X109P, preferably X111V and X109P (according to the EU or Kabat numbering system), and / or the mutations are X126A / G / H / N / P / Q / S / T in the VL (according to the IMGT numbering system). *X stands for any amino acid

[0122] For example, the secondary mutation may be selected from the group consisting of: (a) one or more of the following mutations in the CH1 domain: Y180A, Y180G, Y180I, Y180N, Y180S, Y180T, Y180V, or Y180W, and / or S183N or S183T, and / or V188G, preferably Y180T (according to the EU numbering system), and / or (b) one or more of the following mutations in the CKappa or CLambda (preferably CKappa) domain: A111R, A111T, A111W, or A111V, and / or T109P, preferably T109P and A111V (according to the EU or Kabat numbering system); and / or (c) one of the following mutations in the VL domain: I126A, I126G, I126H, I126N, I126P, I126Q, I126S, or I126T (according to the IMGT numbering system).

[0123] In particular examples, the secondary mutation is one of the following mutations in the CH1 domain: Y180A, Y180G, Y180I, Y180N, Y180S, Y180T, Y180V, or Y180W, and / or S183N or S183T, and / or V188G, preferably Y180T, S183N, and / or S183T, more preferably S183N and / or S183T (according to the EU numbering system).

[0124] In particular examples, the secondary mutation is one or more of the following mutations in the CKappa or CLambda (preferably CKappa) domain: A111R, A111T, A111W, or A111V, and / or T109P, preferably T109P and / or A111V (according to the EU or Kabat numbering system), and / or one of the following mutations in the VL domain: I126A, I126G, I126H, I126N, I126P, I126Q, I126S, or I126T (according to the IMGT numbering system).

[0125] In one embodiment, the mutation is not A111R.

[0126] In a preferred embodiment, in the bispecific antibodies described herein, the secondary mutation at position 180 of the CH1 domain is in the "H1" chain as described herein and / or the "H2" chain as described herein, preferably the "H2" chain.

[0127] In a preferred embodiment, in the bispecific antibodies described herein, the secondary mutation at position 183 of the CH1 domain is in the "H1" chain as described herein and / or the "H2" chain as described herein, preferably the "H2" chain.

[0128] In a preferred embodiment, in the bispecific antibodies described herein, the secondary mutation at position 188 of the CH1 domain is in the "H1" chain as described herein and / or the "H2" chain as described herein, preferably the "H2" chain.

[0129] In a preferred embodiment, in the bispecific antibody described herein, the secondary mutation at position 109 of the CKappa or CLambda (preferably CKappa) domain is in the "H1" chain as described herein and / or the "L1" chain as described herein, preferably the "H1" chain.

[0130] In a preferred embodiment, in the bispecific antibody described herein, the secondary mutation at position 111 of the CKappa or CLambda (preferably CKappa) domain is in the "H1" chain as described herein and / or the "L1" chain as described herein, preferably the "H1" chain.

[0131] In a preferred embodiment, in the bispecific antibodies described herein, the secondary mutation at position 126 of the VL domain is in the "L1" chain as described herein and / or the "L1" chain as described herein, preferably the "H1" chain.

[0132] In a particularly preferred embodiment, the secondary mutations are a pair of secondary mutations, for example a mutation at position 126 in the VL domain and a mutation at position 180 in the CH1 domain.

[0133] In a preferred embodiment, the secondary mutation is at a position selected from the list consisting of: Position 126 of the VL domain and position 180 of the CH1 domain, Position 126 of the VL domain and position 183 of the CH1 domain, Position 126 of the VL domain and position 188 of the CH1 domain, - Position 109 in the CKappa domain and position 180 in the CH1 domain, - Position 109 in the CKappa domain and position 183 in the CH1 domain, - 109th position in the CKappa domain and 188th position in the CH1 domain, - Position 111 in the CKappa domain and position 180 in the CH1 domain, Position 111 of the CKappa domain and position 183 of the CH1 domain, and - Position 111 of the CKappa domain and position 188 of the CH1 domain, preferably position 109 of the CKappa domain and position 183 of the CH1 domain.

[0134] In a particularly preferred embodiment, the secondary mutation pair is selected from the list consisting of: -VL domain mutation I126A and CH1 domain mutation Y180I, -VL domain mutation I126A and CH1 domain mutation Y180W, -VL domain mutation I126A and CH1 domain mutation S183T, -VL domain mutation I126A and CH1 domain mutation V188G, -VL domain mutation I126G and CH1 domain mutation Y180I, -VL domain mutation I126G and CH1 domain mutation Y180W, -VL domain mutation I126G and CH1 domain mutation S183T, -VL domain mutation I126G and CH1 domain mutation V188G, -VL domain mutation I126S and CH1 domain mutation Y180I, -VL domain mutation I126S and CH1 domain mutation Y180W, -VL domain mutation I126S and CH1 domain mutation S183T, -VL domain mutation I126S and CH1 domain mutation V188G, - Mutation T109P in the CKappa domain and mutation Y180I in the CH1 domain, - CKappa domain mutation T109P and CH1 domain mutation Y180W, - CKappa domain mutation T109P and CH1 domain mutation S183T, - CKappa domain mutation T109P and CH1 domain mutation V188G, - A111V mutation in the CKappa domain and Y180I mutation in the CH1 domain; -C Appa domain mutation A111V and CH1 domain mutation Y180W, - CKappa domain mutation A111V and CH1 domain mutation S183T, and -C Appa domain mutation A111V and CH1 domain mutation V188G, Preferably: -VL domain mutation I126S and CH1 domain mutation S183T, -VL domain mutation I126S and CH1 domain mutation V188G, - CKappa domain mutation T109P and CH1 domain mutation S183T, - CKappa domain mutation T109P and CH1 domain mutation V188G, - CKappa domain mutation A111V and CH1 domain mutation S183T, and - The mutation A111V in the CKappa domain and the mutation V188G in the CH1 domain, most preferably the mutation T109P in the CKappa domain and the mutation S183T in the CH1 domain. [Table 5-1] [Table 5-2] [Table 5-3]

[0135] In one embodiment, in an amino acid sequence selected from Table E, the secondary mutation at position 109 of the CKappa or CLambda domain is X 109 and / or a secondary mutation at position 111 of the CKappa or CLambda domain is 111 and / or a secondary mutation at position 126 of the VL domain is 126 In certain embodiments, in an amino acid sequence selected from Table E, the secondary mutation at position 109 of the CKappa domain is X 109 The secondary mutation at position 111 of the CKappa domain is X 111The secondary mutation at position 126 of the VL domain is X 126 In a further embodiment, in an amino acid sequence selected from Table E, the secondary mutation at position 109 of the CKappa or CLambda domain is at position X 109 A secondary mutation at position 111 in the CKappa or CLambda domain is 111 In a further embodiment, in an amino acid sequence selected from Table E, the secondary mutation at position 109 of the CKappa domain is at position X 109 The secondary mutation at position 126 of the VL domain is X 126 In a further embodiment, in an amino acid sequence selected from Table E, the secondary mutation at position 111 of the CKappa domain is at position X 111 The secondary mutation at position 126 of the VL domain is X 126 It is in th place.

[0136] In certain embodiments, in an amino acid sequence selected from Table E, the secondary mutation at position 109 of the CKappa or CLambda domain is X 109 In an alternative specific embodiment, the secondary mutation at position 111 of the CKappa or CLambda domain is at position X 111 In an alternative specific embodiment, in an amino acid sequence selected from Table E, the secondary mutation at position 126 of the VL domain is X 126 The mutation is in the X position. 109 Place, X 111 th, and X 126 It will be understood that if one or two of the positions are absent, the amino acid at the same position from the corresponding wild type amino acid sequence in Table A is included.

[0137] In one embodiment, the amino acid sequence is 109 and / or X 111 and / or X 126 and having at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or at least 95% sequence identity to an amino acid sequence selected from Table E. [Table 6]

[0138] In one embodiment, in an amino acid sequence selected from Table F, the secondary mutation in the CH1 domain at position 180 is X 180 and / or position 183 is X 183 and / or position 188 is X 188 In one embodiment, in an amino acid sequence selected from Table F, the secondary mutation in the CH1 domain at position 180 is X 180 183rd place is X 183 188th place is X 188 In one embodiment, in an amino acid sequence selected from Table F, the secondary mutation in the CH1 domain at position 180 is X 180 183rd place is X 183 In one embodiment, in an amino acid sequence selected from Table F, the secondary mutation in the CH1 domain at position 180 is X 180 188th place is X 188 In one embodiment, in an amino acid sequence selected from Table F, the secondary mutation in the CH1 domain at position 183 is X 183 188th place is X 188 It is in th place.

[0139] In certain embodiments, in an amino acid sequence selected from Table F, the secondary mutation in the CH1 domain at position 180 is X 180 In an alternative specific embodiment, in an amino acid sequence selected from Table F, the secondary mutation in the CH1 domain at position 183 is X 183 In an alternative specific embodiment, in an amino acid sequence selected from Table F, the secondary mutation in the CH1 domain at position 188 is X 188 The mutation is in the X position. 180 Place, X 183 th, and X 188 It will be understood that if one or two of the positions are absent, the amino acid at the same position from the corresponding wild type amino acid sequence of Table C is included.

[0140] In one embodiment, the amino acid sequence is 180 and / or X 183 and / or X 188 and having at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or at least 95% sequence identity to an amino acid sequence selected from Table F.

[0141] As discussed above, the positioning of the mutations in the amino acid sequences described herein refers to numerical values, but it will be understood that this allows for cross-referencing between these particular embodiments and other embodiments in which the mutations are further discussed. Thus, it is also encompassed that the mutations described within the disclosed amino acid sequences may be included in the context of that sequence, but are not included in the overall position designated by the associated number. Thus, as an example, the amino acid sequence AVLQSSGLX 180 SLX 183 SVVEX 188 PSSSLGTQTYICNV (SEQ ID NO: 156) X 180 180th place and / or X 183 183rd position and / or X 188 It is also included that the secondary mutation in the CH1 domain at position 188 can be at one or more of the X positions of the amino acid sequence AVLQSSGLXSLXSVVEXPSSSLGTQTYICNV (SEQ ID NO: 156).

[0142] By way of reference, mutation set 2 - any individual and / or any combination of the mutations listed in Set 2a and Set 2b. Set 2a - CH1 mutations: Y180A, Y180G, Y180I, Y180N, Y180S, Y180T, Y180V, or Y180W, and / or S183N or S183T, and / or V188G, preferably Y180T and / or S183T. Set 2b - C Appa domain mutations: A111R, A111T, A111W, or A111V, and / or T109P, preferably: T109P and / or A111V, and / or variable domain light chain (VL) mutations: I126A, I126G, I126H, I126N, I126P, I126Q, I126S, or I126T.

[0143] In a further embodiment, the secondary mutation may further comprise position 185 of the CH1 domain (according to the EU numbering system).

[0144] In a further embodiment, the secondary mutation may further comprise V185X in the CH1 domain (according to the EU numbering system) *X refers to any amino acid.

[0145] Improved Purity Mutations The "improved purity mutations" described herein may also be referred to as "Optimized RUBY™" mutations, in particular, "Mutation Set 1."

[0146] Bispecific polypeptides in the "RUBY™ format" can be reproducibly produced with excellent levels of purity, while bispecific polypeptides in the "optimized RUBY™ format" having "improved purity variations" can be reproducibly produced with even higher levels of purity.

[0147] It will be appreciated by those skilled in the art that the improved purity mutations may be used in combination with the polypeptides of the invention (preferably bispecific polypeptides) and any of the primary and / or secondary mutations described above.

[0148] In one embodiment of the invention, the improved purity mutation is at position 65 of the VH domain (according to the IMGT numbering system).

[0149] In a preferred embodiment, the improved purity mutation is X65E / A / I in the VH domain. In an alternative preferred embodiment, the improved purity mutation is T65X in the VH domain.

[0150] In a further preferred embodiment, the improved purity mutation in the VH domain is T65E or T65A or T65I.

[0151] In a preferred embodiment, in the bispecific antibodies described herein, the improved purity at position 65 of the VH domain is in the "H1" chain as described herein and / or the "H2" chain as described herein, preferably the "H2" chain. [Table 7]

[0152] In one embodiment, the improved purity mutation at position 65 of the VH domain is X of an amino acid sequence selected from Table G. 65 It is in th place.

[0153] In one embodiment, the amino acid sequence is 65 and having at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or at least 95% sequence identity to an amino acid sequence selected from Table G.

[0154] In a third aspect, the present invention provides a bispecific antibody, the bispecific antibody comprising: (a) an immunoglobulin molecule having specificity for a first antigen, the immunoglobulin molecule comprising two first heavy chain regions and two first light chain regions; (b) two Fab fragments having specificity for a second antigen, the Fab fragments comprising a second heavy chain region and a second light chain region; a second light chain region is fused to the C-terminus of the first heavy chain region; The second heavy chain region comprises a VH domain, the VH domain comprises a protein A binding site, and the VH domain comprises a mutation that reduces or prevents binding of protein A to the protein A binding site.

[0155] In a preferred embodiment of the third aspect of the invention, the polypeptide may comprise any of the mutations described in the second aspect of the invention, as well as any other features described therein.

[0156] Certain embodiments of the third aspect of the invention provide a bispecific antibody, the bispecific antibody comprising: (a) an immunoglobulin molecule having specificity for a first antigen, the immunoglobulin molecule comprising two first heavy chain regions and two first light chain regions; (b) two Fab fragments having specificity for a second antigen, the Fab fragments comprising a second heavy chain region and a second light chain region; a second light chain region is fused to the C-terminus of the first heavy chain region via a linker; the bispecific antibody comprises two H1 chains, each comprising a first heavy chain region of an immunoglobulin, a linker, and a second light chain region of a Fab; two L1 chains, each comprising a first light chain region of an immunoglobulin; and two H2 chains, each comprising a second heavy chain region of a Fab; The two second heavy chain regions (ie, H2) comprise a VH domain that contains a mutation at position 65 (according to the IMGT numbering system).

[0157] As a reference, mutation set 1 - mutations in variable domain heavy (VH): T65E, T65A, T65I.

[0158] Particularly preferred combinations of primary mutations and mutations in "Optimized RUBY™" As discussed above, any of the primary mutations disclosed herein can be combined with the Optimized RUBY™ secondary mutations disclosed herein, and can further be combined with the Optimized RUBY™ improved purity mutations. However, the following are particularly preferred combinations of primary and secondary mutations:

[0159] As discussed above, any combination of primary and secondary mutations, such as any one or more of both the primary mutations in (a) and (b), can be used in the same polypeptide in combination with any one or more of the following secondary mutations in (c) and (d), or variations described herein: (a) T187E (according to the EU numbering system) in the CH1 domain, and / or (b) S114A in the CKappa domain, and (c) Y180T (according to the EU numbering system) in the CH1 domain, and / or (d) T109P and / or A111V (according to the EU or Kabat numbering system) in the CKappa domain.

[0160] Thus, in certain embodiments, a polypeptide combining a primary mutation and a secondary mutation may include the following mutations: In the CH1 domain: Y180T and T187E (according to the EU numbering system), • In the CKappa domain: T109P and / or A111V, and S114A (according to the EU or Kabat numbering system).

[0161] In one embodiment, the primary mutation is a pair of primary mutations at position 114 of the CKappa domain and / or position 187 of the CH1 domain, The secondary mutation is a pair of secondary mutations selected from the list consisting of: - position 126 of the VL domain and / or position 180 of the CH1 domain; - position 126 of the VL domain and / or position 183 of the CH1 domain; - position 126 of the VL domain and / or position 188 of the CH1 domain; - position 109 of the CKappa domain and / or position 180 of the CH1 domain; - position 109 of the CKappa domain and / or position 183 of the CH1 domain; - position 109 of the CKappa domain and / or position 188 of the CH1 domain; - position 111 of the CKappa domain and / or position 180 of the CH1 domain; Position 111 of the CKappa domain and / or position 183 of the CH1 domain, and • Position 111 in the CKappa domain and / or position 188 in the CH1 domain.

[0162] In a preferred embodiment, the primary mutation is a pair of primary mutations S114A in the CKappa domain and / or T187E in the CH1 domain, The secondary mutation is a pair of secondary mutations selected from the list consisting of: the VL domain mutation I126A and / or the CH1 domain mutation Y180I, - the VL domain mutation I126A and / or the CH1 domain mutation Y180W, the VL domain mutation I126A and / or the CH1 domain mutation S183T, the VL domain mutation I126A and / or the CH1 domain mutation V188G, the VL domain mutation I126G and / or the CH1 domain mutation Y180I, the VL domain mutation I126G and / or the CH1 domain mutation Y180W, the VL domain mutation I126G and / or the CH1 domain mutation S183T, the VL domain mutation I126G and / or the CH1 domain mutation V188G, the VL domain mutation I126S and / or the CH1 domain mutation Y180I, the VL domain mutation I126S and / or the CH1 domain mutation Y180W, the VL domain mutation I126S and / or the CH1 domain mutation S183T, the VL domain mutation I126S and / or the CH1 domain mutation V188G, - the mutation T109P in the CKappa domain and / or the mutation Y180I in the CH1 domain, - the mutation T109P in the CKappa domain and / or the mutation Y180W in the CH1 domain, - the mutation T109P in the CKappa domain and / or the mutation S183T in the CH1 domain, - the mutation T109P in the CKappa domain and / or the mutation V188G in the CH1 domain, - the C-Kappa domain mutation A111V and / or the CH1 domain mutation Y180I, - the C Kappa domain mutation A111V and / or the CH1 domain mutation Y180W, The C-Kappa domain mutation A111V and / or the CH1 domain mutation S183T, and CKappa domain mutation A111V and / or CH1 domain mutation V188G, Preferably: the VL domain mutation I126S and / or the CH1 domain mutation S183T, the VL domain mutation I126S and / or the CH1 domain mutation V188G, - the mutation T109P in the CKappa domain and / or the mutation S183T in the CH1 domain, - the mutation T109P in the CKappa domain and / or the mutation V188G in the CH1 domain, The C-Kappa domain mutation A111V and / or the CH1 domain mutation S183T, and the mutation A111V in the C Appa domain and / or the mutation V188G in the CH1 domain, most preferably • The CKappa domain mutation T109P and / or the CH1 domain mutation S183T. [Table 8-1] [Table 8-2]

[0163] In one embodiment, in an amino acid sequence selected from Table H, the primary mutation at position 114 is X 114 A secondary mutation at position 109 in the CKappa or CLambda domain is 109 and / or a secondary mutation at position 111 of the CKappa or CLambda domain is 111 and / or a secondary mutation at position 126 of the VL domain is 126 In certain embodiments, in an amino acid sequence selected from Table H, the primary mutation at position 114 is X 114 The secondary mutation at position 109 of the CKappa domain is X 109 The secondary mutation at position 111 of the CKappa domain is X 111 The secondary mutation at position 126 of the VL domain is X 126 In a further embodiment, in an amino acid sequence selected from Table H, the primary mutation at position 114 is X 114 A secondary mutation at position 109 in the CKappa or CLambda domain is 109 A secondary mutation at position 111 in the CKappa or CLambda domain is 111 In a further embodiment, in an amino acid sequence selected from Table H, the primary mutation at position 114 is X 114 The secondary mutation at position 109 of the CKappa domain is X 109 The secondary mutation at position 126 of the VL domain is X 126 In a further embodiment, in an amino acid sequence selected from Table H, the primary mutation at position 114 is X 114 The secondary mutation at position 111 of the CKappa domain is X 111 The secondary mutation at position 126 of the VL domain is X 126 In certain embodiments, in an amino acid sequence selected from Table H, the primary mutation at position 114 is X 114The primary mutation at position 109 of the CKappa or CLambda domain is X 109 In an alternative specific embodiment, the primary mutation at position 114 is X 114 A secondary mutation at position 111 in the CKappa or CLambda domain is 111 In another particular embodiment, in an amino acid sequence selected from Table H, the primary mutation at position 114 is X 114 The secondary mutation at position 126 of the VL domain is X 126 The mutation is in the X position. 109 Place, X 111 th, and X 126 It will be understood that if one or two of the positions are absent, the amino acid at the same position from the corresponding wild type amino acid sequence in Table A is included.

[0164] In one embodiment, the amino acid sequence has at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or at least 95% sequence identity to an amino acid sequence selected from Table H. 114 and X 109 and / or X 111 and / or X 126 The sequence includes the mutation X 109 Place, X 111 th, and X 126 It will be understood that if one or two of the positions are absent, the amino acid at the same position from the corresponding wild type amino acid sequence of Table A is included. [Table 9]

[0165] In one embodiment, in an amino acid sequence selected from Table I, the primary mutation at position 187 of the CH1 domain is X 187 The secondary mutation at position 180 is X 180 and / or the secondary mutation at position 183 is X 183 and / or the secondary mutation at position 188 is X188 In one embodiment, in an amino acid sequence selected from Table I, the primary mutation at position 187 of the CH1 domain is X 187 The secondary mutation at position 180 is X 180 The secondary mutation at position 183 is X 183 The secondary mutation at position 188 is X 188 In one embodiment, in an amino acid sequence selected from Table I, the primary mutation at position 187 of the CH1 domain is X 187 The secondary mutation at position 180 is X 180 The secondary mutation at position 183 is X 183 In one embodiment, in an amino acid sequence selected from Table I, the primary mutation at position 187 of the CH1 domain is X 187 The secondary mutation at position 180 is X 180 The secondary mutation at position 188 is X 188 In one embodiment, in an amino acid sequence selected from Table I, the primary mutation at position 187 of the CH1 domain is X 187 The secondary mutation at position 183 is X 183 The secondary mutation at position 188 is X 188 It is in the X position. 180 Place, X 183 th, and X 188 It will be understood that where one or two of the positions are absent, the amino acid at the same position from the corresponding wild type amino acid sequence in Table C is included.

[0166] In one embodiment, the amino acid sequence has 10% or more, 20% or more, 30% or more, 40% or more, 50% or more, 60% or more, 70% or more, 80% or more, 90% or more, or 95% or more sequence identity with an amino acid sequence selected from Table I. 187 and X 180 and / or X 183 and / or X 188 The sequence includes the mutation X 180 Place, X 183 th, and X 188It will be understood that if one or two of the positions are absent, the amino acid at the same position from the corresponding wild type amino acid sequence of Table C is included.

[0167] As discussed above, the positioning of the mutations in the amino acid sequences described herein refers to numerical values, but it will be understood that this allows for cross-referencing between these particular embodiments and other embodiments in which the mutations are further discussed. Thus, it is also encompassed that the mutations described within the disclosed amino acid sequences may be included in the context of that sequence, but are not included in the overall position designated by the associated number. Thus, as an example, the amino acid sequence AVLQSSGLX 180 SLX 183 SVVX 187 X 188 The primary mutation at position 187 of the CH1 domain of PSSSLGTQTYICNV (SEQ ID NO: 199) is 187 The secondary mutation at position 180 is X 180 and / or a secondary mutation at position 183 is X 183 and / or a secondary mutation at position 188 is X 188 The amino acid sequence AVLQSSGLX s SLX s SVVX p X s The primary mutation of PSSSLGTQTYICNV (SEQ ID NO: 199) is X P The secondary mutation is at position X S It is also contemplated that the number of positions may be one or more of the following:

[0168] In one embodiment, the primary mutations are a pair of primary mutations at positions 114 in the CKappa domain and 187 in the CH1 domain, the secondary mutations are at two or more of the following positions: position 180 in the CH1 domain, position 183 in the CH1 domain, position 188 in the CH1 domain, position 111 in the CKappa or CLambda (preferably CKappa) domain, position 109 in the CKappa or CLambda (preferably CKappa) domain and position 126 in the VL domain, And / or the polypeptide further comprises a mutation at position 65 of the VH domain.

[0169] In a fourth aspect, the present invention provides a bispecific antibody comprising: (a) an immunoglobulin molecule having specificity for a first antigen, the immunoglobulin molecule comprising two first heavy chain regions and two first light chain regions; (b) two Fab fragments having specificity for a second antigen, the Fab fragments comprising a second heavy chain region and a second light chain region; a second light chain region is fused to the C-terminus of the first heavy chain region; the polypeptide comprises one or more primary mutations to facilitate association of the heavy and light chain regions, which mutations increase the predicted risk of inducing an immunogenic response and / or increase the immunogenicity of the polypeptide; The polypeptide comprises one or more secondary mutations to reduce or avoid the predicted risk of inducing an immunogenic response and / or immunogenicity caused by the one or more primary mutations.

[0170] In a preferred embodiment of the fourth aspect of the invention, the polypeptide may comprise any of the mutations described in the first and / or second aspects of the invention, as well as any other features described therein.

[0171] Certain embodiments of the fourth aspect of the invention provide a bispecific antibody, the bispecific antibody comprising: (a) an immunoglobulin molecule having specificity for a first antigen, the immunoglobulin molecule comprising two first heavy chain regions and two first light chain regions; (b) two Fab fragments having specificity for a second antigen, the Fab fragments comprising a second heavy chain region and a second light chain region; a second light chain region is fused to the C-terminus of the first heavy chain region via a linker; the bispecific antibody comprises two H1 chains, each comprising a first heavy chain region of an immunoglobulin, a linker, and a second light chain region of a Fab; two L1 chains, each comprising a first light chain region of an immunoglobulin; and two H2 chains, each comprising a second heavy chain region of a Fab; the bispecific antibody comprises a mutation at position 114 (according to the EU or Kabat numbering system) of the CKappa or CLambda (preferably CKappa) domains of the two H1 chains and / or at position 187 (according to the EU numbering system) of the CH1 domain of the two H2 chains, The bispecific antibody comprises two or more mutations at the following positions: position 180 in the CH1 domain of the two H2 chains, position 183 in the CH1 domain of the two H2 chains, position 188 in the CH1 domain of the two H2 chains, position 111 in the CKappa or CLambda (preferably CKappa) domain of the two H1 chains, position 109 in the CKappa or CLambda (preferably CKappa) domain of the two H1 chains, and position 126 in the VL domain of the two H1 chains.

[0172] In a fifth aspect, the present invention provides a bispecific antibody, the bispecific antibody comprising: (a) an immunoglobulin molecule having specificity for a first antigen, the immunoglobulin molecule comprising two first heavy chain regions and two first light chain regions; (b) two Fab fragments having specificity for a second antigen, the Fab fragments comprising a second heavy chain region and a second light chain region; a second light chain region is fused to the C-terminus of the first heavy chain region; the polypeptide comprises one or more primary mutations to facilitate association of the heavy and light chain regions, which mutations increase the predicted risk of inducing an immunogenic response and / or increase the immunogenicity of the polypeptide; the polypeptide comprises one or more secondary mutations to reduce or avoid the predicted risk of inducing an immunogenic response and / or immunogenicity caused by one or more primary mutations, The second heavy chain region comprises a VH domain, the VH domain comprises a protein A binding site, and the VH domain comprises a mutation that reduces or abolishes binding of protein A to the protein A binding site.

[0173] In a fifth embodiment of the third aspect of the invention, the polypeptide may comprise any of the mutations described in the first and / or second aspects of the invention, as well as any other features described therein.

[0174] Certain embodiments of the fifth aspect of the invention provide a bispecific antibody, the bispecific antibody comprising: (a) an immunoglobulin molecule having specificity for a first antigen, the immunoglobulin molecule comprising two first heavy chain regions and two first light chain regions; (b) two Fab fragments having specificity for a second antigen, the Fab fragments comprising a second heavy chain region and a second light chain region; a second light chain region is fused to the C-terminus of the first heavy chain region via a linker; the bispecific antibody comprises two H1 chains, each comprising a first heavy chain region of an immunoglobulin, a linker, and a second light chain region of a Fab; two L1 chains, each comprising a first light chain region of an immunoglobulin; and two H2 chains, each comprising a second heavy chain region of a Fab; the bispecific antibody comprises a mutation at position 114 (according to the EU or Kabat numbering system) of the CKappa or CLambda (preferably CKappa) domains of the two H1 chains and / or at position 187 (according to the EU numbering system) of the CH1 domain of the two H2 chains, The bispecific antibody comprises two or more mutations at the following positions: position 180 in the CH1 domain of the two H2 chains, position 183 in the CH1 domain of the two H2 chains, position 188 in the CH1 domain of the two H2 chains, position 111 in the CKappa or CLambda (preferably CKappa) domain of the two H1 chains, position 109 in the CKappa or CLambda (preferably CKappa) domain of the two H1 chains, and position 126 in the VL domain of the two L1 chains. The two second heavy chain regions (ie, H2) comprise a VH domain that contains a mutation at position 65 (according to the IMGT numbering system).

[0175] Additional Mutations That Can Be Combined With the Mutations Described Herein In addition to the "primary mutations," "secondary mutations," and "improved purity mutations" described herein, the following "additional mutations" may also be included in the polypeptides of the invention. These additional mutations are those described for the "RUBY™ format" in pending UK Patent Application No. 1820556.7 and PCT Application No. WO2020 / 127354, and are not the primary mutations described herein.

[0176] In one embodiment, the additional mutations are one or more mutations to enhance association between an immunoglobulin heavy chain polypeptide and an immunoglobulin light chain polypeptide, and / or one or more mutations to enhance association between a Fab heavy chain polypeptide and a Fab light chain polypeptide.

[0177] In one embodiment, the one or more additional mutations prevent the formation of aggregates and Fab by-products.

[0178] It will be appreciated by those skilled in the art that in one embodiment, additional mutations may prevent the formation of aggregates and / or by-products by creating steric hindrance and / or charge incompatibility.

[0179] "Steric hindrance" refers to the retardation of the reaction due to steric bulk, i.e., the size of the amino acid molecule prevents association of two protein surfaces that might otherwise occur when a smaller amino acid is present.

[0180] "Incompatibility between charges" means that unwanted products are not formed because the charges are incompatible and prevent product formation (e.g., there may be two negatively charged moieties that prevent the formation of unwanted products).

[0181] As described above, the additional mutations limit the formation of Fab by-products and / or aggregates, for example, by generating surfaces that limit the formation of aggregates or by-product Fab fragments. In one embodiment, the primary mutations prevent the formation of Fab by-products by generating steric hindrance and / or charge incompatibility (resulting in charge incompatibility of the wrong chains). The primary mutations may also promote correct inter-chain (i.e., between a first heavy chain polypeptide and a first light chain polypeptide, and / or between a second heavy chain polypeptide and a second light chain polypeptide) interactions, for example, by generating salt or disulfide bridges.

[0182] Thus, additional mutations may be advantageous in forming bispecific polypeptides.

[0183] In one embodiment, the percentage of aggregates formed during production is 25% or less. Optionally, the percentage of aggregates is 20%, 17.5%, 15%, 13.5%, or 10% or less. Preferably, the percentage of aggregates is less than 10%. Optionally, these measurements are made when the chains of the bispecific polypeptide are transfected in equal ratios (e.g., in a 1:1:1 ratio when three chains are used during production).

[0184] Alternatively, the transfection ratio of the strands can be optimized. Optionally, the percentage of aggregates when optimizing the transfection ratio of the strands can be 3.5%, 3%, 2.5%, or 2% or less.

[0185] In one embodiment, the bispecific polypeptide comprises one or more pairs of mutations, each of which comprises two functionally compatible mutations.

[0186] By "functionally compatible mutations" is meant that the mutations have complementary functions, for example, one mutation (in one strand) of the pair can be a mutation that creates a positively charged region and the other mutation (in the other strand) can be a mutation that creates a negatively charged region. These mutations act together in a functionally compatible manner to promote association of the respective chains.

[0187] In one embodiment, the bispecific polypeptide comprises one or more additional pairs of mutations in one or more of the following regions: (a) the CH1 region and the CKappa or CLambda region of an immunoglobulin, and / or (b) the CH1 region and the C Appa or C Lambda region of the Fab, and / or (c) the VL and VH regions of an immunoglobulin, and / or (d) VL and VH regions of Fab.

[0188] Thus, in one embodiment, the additional mutation pairs are in the CH1 region and the CKappa or CLambda region of the Fab and / or immunoglobulin, and the primary mutation pairs are selected from: (a) deformation of the concave and convex surfaces (i.e., stereochemical deformation); and / or (b) hydrophobic swap mutations, and / or (c) charge mutations (i.e., salt mutations), and / or (d) Mutations that result in the formation of disulfide bridges.

[0189] Additional pairs of mutations may alternatively or additionally be in the VH and VL regions of the Fab and / or immunoglobulin, the primary pairs of mutations in the VH and VL regions being selected from: (a) charge mutations (i.e., salt mutations), and / or (b) a doubly charged mutation, and / or (c) Mutations that result in the formation of disulfide bridges.

[0190] In one embodiment of the invention, the additional mutation is at a position selected from the group consisting of: (a) one or more of the following positions in the CH1 domain: positions 168, 170, and 145 (according to the EU numbering system); and / or (b) at one or more of the following position ranges in the CKappa or CLambda domain: positions 132-138, 173-179, 130-136, 111-117, and 134-140 (according to the EU numbering system); and / or (c) a position selected from one or more of the following position ranges in the VL: positions 41-47, 117-123, and 46-52 (according to the IMGT numbering system); and / or (d) a position selected from one or more of the following position ranges in VH: positions 41-47, 46-52, and 117-123 (according to the IMGT numbering system).

[0191] In one embodiment of the invention, the additional mutation is at a position selected from the group consisting of: (a) one or more of the following positions in the CH1 domain: positions 168, 170, and 145 (according to the EU numbering system); and / or (b) at one or more of the following position ranges in the CKappa or CLambda domain: 132-138, 173-179, 130-136, 111-117, and 134-140 (according to the Kabat numbering system); and / or (c) a position selected from one or more of the following position ranges in the VL: positions 41-47, 117-123, and 46-52 (according to the IMGT numbering system); and / or (d) a position selected from one or more of the following position ranges in VH: positions 41-47, 46-52, and 117-123 (according to the IMGT numbering system).

[0192] In one embodiment of the invention, the additional mutation is at a position selected from the group consisting of: (a) one or more of the following positions in the CH1 domain: positions 168, 170, and 145 (according to the EU numbering system); and / or (b) at one or more of the following position ranges in the CKappa or CLambda domain: positions 132-138, 173-179, 130-136, 111-117, and 134-140 (according to the EU numbering system); and / or (c) a position selected from one or more of the following position ranges in the VL: positions 41-47, 117-123, and 46-52 (according to the IMGT numbering system); and / or (d) a position selected from one or more of the following position ranges in VH: positions 41-47, 46-52, and 117-123 (according to the IMGT numbering system).

[0193] A single mutation in each of the ranges given above will be a relevant functional mutation since it will be at a position that contacts amino acids in the corresponding domain / chain and therefore at the relevant interface between the chains.

[0194] Thus, it will be appreciated by those skilled in the art that additional mutations in the position ranges given above are suitable since the relevant functional characteristic is whether the position contacts the corresponding position on the other chain, i.e. whether the relevant position is a position of the VH chain that contacts the corresponding position of the VL chain, or whether the relevant position is a position of the CLambda that contacts a position of the CH1 chain.

[0195] In a preferred embodiment of the invention, the additional mutation is at a position selected from the group consisting of: (a) one or more of the following positions in the CH1 domain: positions 168, 170, and 145 (according to the EU numbering system); and / or (b) one or more of the following positions in the CKappa or CLambda domain: positions 114, 133, 135, 137, and 176 (according to the Kabat numbering system); and / or (c) one or more of the following positions in the VL domain: positions 44, 49, and 120 (according to the IMGT numbering system); and / or (d) one or more of the following positions in the VH domain: positions 44, 49, and 120 (according to the IMGT numbering system).

[0196] In one embodiment of the invention, the additional mutation is at a position selected from the group consisting of: (a) one or more of the following positions in the CH1 domain: positions 168, 170, and 145 (according to the EU numbering system); and / or (b) one or more of the following positions in the CKappa or CLambda domain: positions 114, 133, 135, 137, and 176 (according to the EU numbering system); and / or (c) one or more of the following positions in the VL domain: positions 44, 49, and 120 (according to the IMGT numbering system); and / or (d) one or more of the following positions in the VH domain: positions 44, 49, and 120 (according to the IMGT numbering system).

[0197] In one embodiment, the additional mutation is selected from the group consisting of: VH X44R / E / D / K, X49C, X120K VL X44R / E / D / K, X49D X120C CH1 X168A / G, X170G / A, and X145Q CKappa / CLambda X114A, X133T, X135Y / W, X137K / R / H, X176W / V / Y *Numbering is according to the IMGT system for VH / VL domains and the EU numbering system for constant domains *X stands for any amino acid

[0198] The use of " / " in contexts where mutations are discussed is to illustrate alternative amino acids, for example, "X44R / E / D / K" indicates that R or E or D or K can be included at position 44 as alternatives to the amino acid "X".

[0199] In one embodiment, the additional mutation is selected from the group consisting of: VH X44R / E / D / K, X49C, X120K VL X44R / E / D / K, X49D X120C CH1 X168A / G, X170G / A, X145Q CKappa / CLambda X114A, X133T, X135Y / W, X137K / R / H, X176W / V / Y *Numbering is according to the IMGT system for VH / VL domains and the Kabat numbering system for constant domains *X stands for any amino acid

[0200] In one embodiment, the additional mutation is selected from the group consisting of: VH Q44X, G49X, Q120X VL Q44X, A49X, Q120X CH1 H168X, F170X, L145X, CKappa / CLambda S / T114X, V133X, L135X, N / S137X, S176X *Numbering is according to the IMGT system for VH / VL domains and the EU numbering system for constant domains *X stands for any amino acid

[0201] In one embodiment, the additional mutation is selected from the group consisting of: VH Q44X, G49X, Q120X VL Q44X, A49X, Q120X CH1 H168X, F170X, L145X CKappa / CLambda S / T114X, V133X, L135X, N / S137X, S176X *Numbering is according to the IMGT system for VH / VL domains and the Kabat numbering system for constant domains *X stands for any amino acid

[0202] In one embodiment of the invention, the additional mutation is at a position selected from the group consisting of: (a) one or more of the following positions in the CH1 domain: H168, F170, and L145 (according to the EU numbering system); and / or (b) one or more of the following positions in the CKappa domain: L135, S176, V133, and N137 (according to the EU numbering system), and / or one or more of the following positions in the CLambda domain: L135, S176, V133, and S137 (according to the Kabat numbering system), and / or (c) one or more of the following positions in the VL domain: Q44, Q120, and A49 (according to the IMGT numbering system); and / or (d) one or more of the following positions in the VH domain: Q44, G49, and Q120 (according to the IMGT numbering system).

[0203] For example, the additional mutation may be selected from the group consisting of: (a) one or more of the following mutations in the CH1 domain: H168A, F170G, and L145Q (according to the EU numbering system); and / or (b) one or more of the following mutations in the CKappa domain: L135Y, S176W, V133T, S176V, and N137K (according to the EU numbering system), and / or one or more of the following mutations in the CLambda domain: L135Y, S176W, V133T, S176V, and S137K (according to the Kabat numbering system), and / or (c) one or more of the following mutations in the VL domain: Q44R, Q44E, Q120C, Q44D, and A49D (according to the IMGT numbering system); and / or (d) one or more of the following mutations in the VH domain: Q44E, Q44R, G49C, Q44K, and Q120K (according to the IMGT numbering system).

[0204] In a preferred embodiment, in the bispecific antibodies described herein, the additional mutation at position 44 of the VH domain is in the "H1" chain as described herein and / or the "H2" chain as described herein.

[0205] In a preferred embodiment, in the bispecific antibodies described herein, the additional mutation at position 44 of the VL domain is in the "H1" chain as described herein and / or the "L1" chain as described herein.

[0206] In a preferred embodiment, in the bispecific antibodies described herein, the additional mutation at position 49 of the VH domain is in the "H1" chain as described herein and / or the "H2" chain as described herein.

[0207] In a preferred embodiment, in the bispecific antibodies described herein, the additional mutation at position 49 of the VL domain is in the "H1" chain as described herein and / or the "L1" chain as described herein.

[0208] In a preferred embodiment, in the bispecific antibodies described herein, the additional mutation at position 120 of the VH domain is in the "H1" chain as described herein and / or the "H2" chain as described herein.

[0209] In a preferred embodiment, in the bispecific antibodies described herein, the additional mutation at position 120 of the VL domain is in the "H1" chain as described herein and / or the "L1" chain as described herein.

[0210] In a preferred embodiment, in the bispecific antibodies described herein, the additional mutation at position 168 of the CH1 domain is in the "H1" chain as described herein and / or the "H2" chain as described herein.

[0211] In a preferred embodiment, in the bispecific antibodies described herein, the additional mutation at position 170 of the CH1 domain is in the "H1" chain described herein and / or the "H2" chain described herein.

[0212] In a preferred embodiment, in the bispecific antibodies described herein, the additional mutation at position 145 of the CH1 domain is in the "H1" chain as described herein and / or the "H2" chain as described herein.

[0213] In a preferred embodiment, in the bispecific antibodies described herein, the additional mutation at position 133 of the CKappa or CLambda (preferably CKappa) domain is in the "H1" chain as described herein and / or the "L1" chain as described herein.

[0214] In a preferred embodiment, in the bispecific antibodies described herein, the additional mutation at position 135 of the CKappa or CLambda (preferably CKappa) domain is in the "L1" chain as described herein and / or the "H1" chain as described herein.

[0215] In a preferred embodiment, in the bispecific antibodies described herein, the additional mutation at position 176 of the CKappa or CLambda (preferably CKappa) domain is in the "L1" chain as described herein and / or the "H1" chain as described herein.

[0216] In a preferred embodiment, in the bispecific antibodies described herein, the additional mutation at position 137 of the CKappa or CLambda (preferably CKappa) domain is in the "H1" chain described herein and / or the "L1" chain described herein.

[0217] In certain embodiments, the additional mutations are as follows: at position 44 of the VH domain (e.g., Q44R and / or Q44E); at position 44 of the VL domain (e.g., Q44R and / or Q44E); at positions 168 and 170 of the CH1 domain (e.g., H168A and F170G); and - At positions 137, 135 and 176 (such as N137K or S137K, L135Y and S176W) of the CKappa or CLambda (preferably CKappa) domain.

[0218] In particularly preferred embodiments, in the bispecific antibodies described herein, the additional mutations are as follows: - At position 44 (e.g., Q44R) in the VH domain of the "H1" chain; ● At position 44 (e.g., Q44R) in the VL domain of the "H1" chain, ● At position 44 (e.g., Q44E) in the VH domain of the "H2" chain, ● At position 44 (e.g., Q44E) in the VL domain of the "L1" chain; - At positions 168 and 170 (e.g., H168A and F170G) in the CH1 domain of the "H1" chain; - at position 137 (such as N137K or S137K) of the CKappa or CLambda (preferably CKappa) domain of the "H1" chain, and - At positions 135 and 176 (such as L135Y and S176W) in the CKappa or CLambda (preferably CKappa) domain of the "L1" chain.

[0219] Polypeptide Binding Targets In one embodiment, the bispecific polypeptide is tetravalent and capable of bivalently binding to each of two antigens.

[0220] In one embodiment, the bispecific polypeptide comprises an immunoglobulin arranged as an antibody with two arms, and thus comprising two binding sites for a first antigen and two binding sites for Fab fragments, each of which provides a binding site for a second antigen, so that there are two binding sites for the first antigen and two binding sites for the second antigen.

[0221] In one embodiment, the antigen (such as the first antigen and / or the second antigen) is an immunomodulator.

[0222] By "immunomodulator" is meant a target capable of modifying an immune response or function of the immune system. In one embodiment, an immunomodulator is a checkpoint molecule. By "checkpoint molecule" is meant a regulator of the immune system.

[0223] It will be appreciated by those skilled in the art that a checkpoint molecule (such as CD40) may be a stimulatory or inhibitory checkpoint molecule.

[0224] In one embodiment, the antigen (such as the first antigen and / or the second antigen) is a tumor cell-associated antigen (TAA).

[0225] Thus, the tumor cell associated antigen may be selected from the group consisting of: a) mutated oncogene and tumor suppressor gene products, b) overexpressed or aberrantly expressed cellular proteins; c) tumor antigens produced by oncogenic viruses; d) carcinoembryonic antigen, e) altered cell surface glycolipids and glycoproteins; f) cell type specific differentiation antigen; g) hypoxia-inducible antigens; h) tumor peptides presented by MHC class I; i) epithelial tumor antigens, j) hematological tumor associated antigens, k) cancer testis antigens, and l) Melanoma antigen.

[0226] In one embodiment, the TAA is EpCAM, 5T4, and / or CEACAM5.

[0227] variant The polypeptides or binding domains thereof described herein (such as EpCAM or CD40 binding domains) may comprise variants or fragments of any of the specific amino acid sequences listed herein, so long as the polypeptide or binding domain retains binding to the target. In one embodiment, an antibody variant or antigen-binding fragment may retain the CDR sequences of the sequences listed herein.

[0228] A fragment of any one of the heavy or light chain amino acid sequences listed herein may comprise at least 7, at least 8, at least 9, at least 10, at least 12, at least 15, at least 18, at least 20, at least 25, at least 50, at least 60, at least 70, at least 80, at least 90, or at least 100 consecutive amino acids from the amino acid sequence.

[0229] A variant of any one of the heavy or light chain amino acid sequences listed herein may be a substitution, deletion, or addition variant of the sequence. A variant may include one, two, three, four, five, up to ten, up to twenty, up to thirty or more amino acid substitutions and / or deletions from the sequence. A "deletion" variant may include the deletion of an individual amino acid, the deletion of a small group of amino acids, such as two, three, four, or five amino acids, or the deletion of a larger region of amino acids, such as the deletion of a particular amino acid domain or other feature. A "substitution" variant preferably involves replacing one or more amino acids with the same number of amino acids, making conservative amino acid substitutions. For example, an amino acid may be replaced with an alternative amino acid having similar properties, such as another basic amino acid, another acidic amino acid, another neutral amino acid, another charged amino acid, another hydrophilic amino acid, another hydrophobic amino acid, another polar amino acid, another aromatic amino acid, or another aliphatic amino acid. Some properties of the 20 main amino acids that can be used to select suitable replacements are as follows: [Table 10]

[0230] Amino acids herein may be referred to by their full name, their three letter code, or their one letter code.

[0231] Preferred "derivatives" or "variants" include those in which an amino acid that appears in the sequence instead of a naturally occurring amino acid is a structural analog thereof. The amino acids used in the sequence may be derivatized or modified, e.g., labeled, so long as the function of the antibody is not significantly adversely affected.

[0232] The above derivatives and variants may be prepared during the synthesis of the antibody or by post-production modification, or if the antibody is recombinant, using known techniques of site-directed mutagenesis, random mutagenesis, or enzymatic cleavage and / or ligation of nucleic acids.

[0233] Preferably, the variant has an amino acid sequence that has more than 60%, or more than 70%, such as 75 or 80%, preferably more than 85%, such as more than 90 or 95% amino acid identity with the sequence as shown in the sequences disclosed herein. This level of amino acid identity can be found over the entire length of the sequence of the relevant SEQ ID NO, or over a portion of the sequence, such as over 20, 30, 50, 75, 100, 150, 200 or more amino acids, depending on the size of the full length polypeptide.

[0234] "Sequence identity," in the context of amino acid sequences, refers to sequences having the recited values ​​when assessed using ClustalW (Thompson et al., 1994, Nucleic Acids Res. 22(22):4673-80; the disclosure of which is incorporated herein by reference) using the following parameters: Pairwise alignment parameters-method: exact, matrix: PAM, gap open penalty: 10.00, gap extension penalty; 0.10; Multiple alignment parameters - matrix: PAM, gap open penalty: 10.00, % identity for delay: 30, end gap penalty: on, gap separation distance: 0, negative matrix: none, gap extension penalty: 0.20, residue specific gap penalty: on, hydrophilic gap penalty: on, hydrophilic residues: GPSNDQEKR. Sequence identity at specific residues is intended to include identical residues that have only been derivatized.

[0235] Functional properties Those skilled in the art will also understand that the polypeptides of the present invention can be defined in terms of their functional properties and effects.

[0236] In one embodiment, a polypeptide of the invention is capable of inducing antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), complement-dependent cytotoxicity (CDC), and / or apoptosis.

[0237] In one embodiment, the polypeptide is capable of inducing: (a) B cell activation, and / or (b) dendritic cell activation, and / or (c) activation of cytotoxic T cells (i.e., CD8+ T cells); and / or (d) activation of helper T cells (i.e., CD4+ T cells); and / or (e) improving cross-presentation of tumor antigens by dendritic cells; and / or (f) proliferation of tumor antigen-specific T cells; and / or (g) direct tumor cell killing via ADCC and / or via inhibition of tumor proliferation and survival signals; and / or (h) antiangiogenic effects via interactions with endothelial cells and / or stromal cells; and / or (i) activation of natural killer cells, and / or (j) depletion of Tregs, and / or (k) reprogramming Tregs into effector T cells; and / or (l) depletion of tumor myeloid cell populations, and / or (m) reprogramming tumor myeloid cell populations; and / or (n) internalization of tumor debris by antigen-presenting cells, and / or (o) internalization of tumor extracellular vesicles (e.g., exosomes) by antigen-presenting cells; and / or (p) Localization to tumor tissue by binding to tumor cells.

[0238] Methods for determining whether a polypeptide is capable of inducing the functional effects listed above are known to the person skilled in the art and are also exemplified in the examples of the present application.

[0239] The polypeptides can modulate the activity of cells expressing a T cell target, said modulation being an increase or decrease in the activity of said cells. The cells are typically T cells. The antibodies can increase the activity of CD4+ or CD8+ effector cells, or decrease the activity of regulatory T cells (Tregs). In either case, the net effect of the antibody will be an increase in the activity of effector T cells.

[0240] Methods for determining changes in effector T cell activity are well known, including, for example, measuring an increase in the level of T cell IL-2 or IFN-γ production in the presence of an antibody, or an increase in T cell proliferation, compared to the level of T cell IL-2 or IFN-γ production and / or T cell proliferation in the presence of a control. Assays for cell proliferation and / or IL-2 or IFN-γ production are well known, and assays are also illustrated in the Examples. Additional methods for determining changes in effector T cell activity include measuring changes in T cell expression, for example, CD25, CD69, ICOS, EOMES, CD107a, and / or granzyme B, or measuring changes in T cell proliferation, for example, by using CFSE or by measuring the level of Ki67, both of which can be achieved using flow cytometry-based methods.

[0241] Methods for determining changes in Treg cell activity are well known and include, for example, measuring reprogramming of Treg cells to Th cells in in vitro assays by assessing TGF-β and IFN-γ production, or by measuring the suppressive capacity of Treg cells in vitro (co-culture CD3 / CD28 stimulated CD4+ T cells with Treg cells and assessing proliferation of CD4+ T cells using CFSE or other similar proliferation dyes), or by measuring the level of differentiation of Treg cells in in vitro assays (culture CD4+ T cells under conditions that promote polarization into inducible Treg (iTreg) cells and measure the frequency of low CD127 FoxP3+ iTreg cells). Additional methods for determining antibody-induced changes in Treg cell activity include ADCC reporter assays to determine depletion of Treg cells or other ADCC reporter assays (co-culture Treg cells with NK cells or macrophages and determine depletion of Treg cells using LDH release or various viability stains).

[0242] Methods for determining changes in NK cell activity are well known and include, for example, measuring changes in expression of CD25, CD107a, Granzyme B, or NKG2D by flow cytometry-based methods or in in vitro assays (wherein the effect of an antibody on NK cell function can be measured by the release of cytokines and lytic enzymes (e.g., IFN-γ, TNF-α, or perforin)).

[0243] In one embodiment, the polypeptide is capable of inducing an increase in the activity of effector T cells, optionally at least 1.5-fold, 4.5-fold, or 7-fold higher than the increase in effector T cell activity induced by a combination of an immunoglobulin molecule and a Fab fragment administered to the T cells as separate molecules. This can be tested in vitro in a T cell activation assay, for example by measuring the production of IL-2 or IFN-γ. Activation of effector T cells would mean that a tumor-specific T cell response can be achieved in vivo. Furthermore, an anti-tumor response in an in vivo model, such as a mouse model, would mean that the immune response against the tumor was successful. This would therefore indicate that the bispecific antibody is capable of inducing tumor immunity.

[0244] In one embodiment, the polypeptide induces increased activation of antigen presenting cells, such as B cells or dendritic cells.

[0245] It will be understood by those skilled in the art that said increase in activation can be an increase in the expression of the costimulatory molecules CD80 or CD86, or an increase in the production of IL-12, or an increase in the ability to present antigens (e.g., tumor antigens) to MHC class I or II to T cells (and by so-called cross-presentation, antigens taken up by internalization induced by bispecific antibodies (e.g., induced by the exemplary bispecific CD40-EPCAM antibody) can finally be presented to MHC class I molecules, generating enhanced activation of T cells that recognize said antigen by antigen-presenting cells).

[0246] In one embodiment, the polypeptide induces increased uptake of tumor debris or tumor extracellular vesicles by antigen-presenting cells, such as B cells or dendritic cells.

[0247] Those skilled in the art will understand that the increased uptake can be measured by colocalization or internalization of tumor debris or tumor extracellular vesicles by antigen-presenting cells. Increased uptake of tumor debris or tumor extracellular vesicles by antigen-presenting cells will then expand the repertoire of T cells, thus resulting in more effective T cell-mediated tumor eradication. Methods for determining the proliferation of tumor antigen-specific T cells are well known, including, for example, the use of MHC-peptide multimers (e.g., tetramers or pentamers). Such proliferation can be measured by inoculating mice with tumors expressing specific tumor antigens, or tumors transfected with tumor model antigens (e.g., ovalbumin), or by inoculating mice with the same cells that have been heat-shocked to induce necrosis, followed by measuring the proliferation of tumor antigen-specific T cells by using various MHC-tumor (model) antigen peptide tetramers or pentamers by flow cytometry-based methods.

[0248] In one embodiment, the polypeptide is 100×10 -9 Less than M or 50 x 10 -9 Less than M or 25 x 10 -9 Less than M, preferably 10, 9, 8, 7, or 6 x 10 -9 M or less, more preferably 5, 4, 3, 2, or 1×10 -9 Less than M, most preferably 9×10 -10 K under M D and binds to an antigen (such as a first antigen and / or a second antigen).

[0249] Standard assays for evaluating the binding ability of a ligand to a target are well known in the art, including, for example, ELISA, Western blot, RIA, and flow cytometry analysis. The binding kinetics (e.g., binding affinity) of a bispecific antibody can also be evaluated by standard assays known in the art, such as by surface plasmon resonance analysis (SPR). Such assays are also demonstrated in the examples of this application.

[0250] The terms "binding activity" and "binding affinity" are intended to refer to the tendency of a polypeptide molecule to bind or not bind to a target. Binding affinity can be quantified by determining the dissociation constant (Kd) of a polypeptide and its target. A lower Kd indicates a higher affinity for the target. Similarly, the specificity of the binding of a polypeptide to its target can be defined in terms of the comparative dissociation constant (Kd) of the polypeptide for its target, compared to the dissociation constant for the polypeptide and another non-target molecule.

[0251] The value of this dissociation constant can be determined directly by well-known methods, and even for complex mixtures, it can be calculated by methods such as those described in Caceci et al. (Byte 9:340-362, 1984; the disclosure of which is incorporated herein by reference). For example, Kd can be established using a double-filter nitrocellulose filter binding assay such as that disclosed in Wong & Lohman (Proc. Natl. Acad. Sci. USA 90, 5428-5432, 1993). Other standard assays for evaluating the binding ability of a ligand, such as an antibody, to a target are known in the art, including, for example, ELISA, Western blot, RIA, and flow cytometry analysis. The binding rate (e.g., binding affinity) of an antibody can also be evaluated by standard assays known in the art, such as Biacore™ system analysis.

[0252] Competitive binding assays may be performed in which the binding of a polypeptide to a target is compared to the binding of the target by another known ligand of the target, such as another antibody. The concentration at which 50% inhibition occurs is known as Ki. Under ideal conditions, Ki is equivalent to Kd. Since Ki values ​​are never less than Kd, it is convenient to substitute the measured value of Ki to determine an upper limit for Kd.

[0253] Alternative measures of binding affinity include EC50 or IC50. In this context, EC50 refers to the concentration at which a polypeptide achieves 50% of its maximum binding to a given amount of target. IC50 refers to the concentration at which a polypeptide inhibits 50% of the maximum binding of a given amount of competitor to a given amount of target. In both cases, a lower level of EC50 or IC50 indicates a higher affinity to the target. Both the EC50 value and IC50 value of a ligand to its target can be determined by well-known methods, such as ELISA. Suitable assays for evaluating the EC50 and IC50 of a polypeptide are described in the examples.

[0254] A polypeptide of the invention is preferably capable of binding to one of its targets with an affinity that is at least 2-fold, 10-fold, 50-fold, 100-fold or more than its affinity for binding to another non-target molecule.

[0255] Polynucleotides, Vectors, and Cells The present invention also relates to polynucleotides that encode all or part of the polypeptides of the present invention. Thus, the polynucleotides of the present invention may encode any of the polypeptide chains described herein. The terms "nucleic acid molecule" and "polynucleotide" are used interchangeably herein and refer to polymeric forms of nucleotides of any length, whether deoxyribonucleotides or ribonucleotides, or analogs thereof. Non-limiting examples of polynucleotides include genes, gene fragments, messenger RNA (mRNA), cDNA, recombinant polynucleotides, plasmids, vectors, isolated DNA of any sequence, isolated RNA of any sequence, nucleic acid probes, and primers. The polynucleotides of the present invention may be provided in isolated or substantially isolated form. By substantially isolated, it is meant that there may be substantial, but not complete, isolation of the polypeptide from any surrounding medium. The present polynucleotides may be considered to be substantially isolated even when mixed with carriers or diluents that do not interfere with their intended use.

[0256] A nucleic acid sequence "encoding" a selected polypeptide is a nucleic acid molecule that is transcribed (in the case of DNA) and translated (in the case of mRNA) into a polypeptide in vivo when placed under the control of appropriate regulatory sequences. The boundaries of the coding sequence are determined by a start codon at the 5' (amino) terminus and a translation stop codon at the 3' (carboxy) terminus. As used herein, such nucleic acid sequences can include, but are not limited to, cDNA derived from viral, prokaryotic or eukaryotic mRNA, genomic sequences derived from viral or prokaryotic DNA or RNA, and even synthetic DNA sequences. A transcription termination sequence may be located 3' to the coding sequence.

[0257] Thus, a polypeptide of the present invention may be produced from or delivered in the form of a polynucleotide that encodes and is capable of expressing it.

[0258] The polynucleotides of the present invention can be synthesized by methods well known in the art, as described for example in Green & Sambrook (2012, Molecular Cloning - a laboratory manual, 4th edition; Cold Spring Harbor Press; the disclosure of which is incorporated herein by reference).

[0259] The nucleic acid molecules of the invention may be provided in the form of expression cassettes comprising control sequences operably linked to the inserted sequence, thus allowing the expression of the polypeptides of the invention in vivo. These expression cassettes are likewise typically provided within vectors (e.g., plasmids or recombinant viral vectors). Such expression cassettes may be administered directly to the host subject. Alternatively, a vector comprising the polynucleotides of the invention may be administered to the host subject. Preferably, the polynucleotides are prepared and / or administered using a genetic vector. A suitable vector may be any vector capable of carrying a sufficient amount of genetic information and allowing the expression of the polypeptides of the invention.

[0260] Thus, the present invention includes expression vectors comprising such polynucleotide sequences. Such expression vectors are routinely constructed in the art of molecular biology and may involve, for example, the use of plasmid DNA and appropriate initiators, promoters, enhancers, and other elements, such as polyadenylation signals, that may be necessary to allow expression of the peptides of the present invention and positioned in the correct orientation. Other suitable vectors will be apparent to those skilled in the art (Green & Sambrook, supra).

[0261] The present invention includes cells modified to express the bispecific antibodies or constituent polypeptides of the present invention. Such cells include transient or preferably stable higher eukaryotic cell lines, such as mammalian or insect cells, lower eukaryotic cells, such as yeast, or prokaryotic cells, such as bacterial cells. Particular examples of cells that may be modified by insertion of vectors or expression cassettes encoding the polypeptides of the present invention include mammalian HEK293T, CHO, HeLa, NS0, and COS cells. Preferably, the cell line selected is not only stable, but also allows mature glycosylation and cell surface expression of the polypeptide.

[0262] Such cell lines of the invention may be cultured using conventional methods to produce the polypeptides of the invention or may be used therapeutically or prophylactically to deliver antibodies of the invention to a subject. Alternatively, the polynucleotides, expression cassettes, or vectors of the invention may be administered ex vivo to cells derived from a subject and then the cells are returned to the subject's body.

[0263] In a further aspect, the present invention provides a method of producing any of the polypeptides and / or bispecific antibodies disclosed herein.

[0264] Pharmaceutical Formulations, Therapeutic Uses, and Patient Populations In another aspect, the invention provides compositions comprising molecules of the invention, such as the polypeptides, polynucleotides, vectors, and cells described herein. For example, the invention provides compositions comprising one or more molecules of the invention, such as one or more polypeptides of the invention, and at least one pharma- ceutically acceptable carrier.

[0265] As used herein, a "pharmaceutically acceptable carrier" includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like that are physiologically compatible. Preferably, the carrier is suitable for parenteral administration, e.g., intravenous, intramuscular, or subcutaneous administration (e.g., by injection or infusion). Depending on the route of administration, the polypeptide may be coated with a material to protect the polypeptide from the action of acids and other natural conditions that may inactivate or denature the polypeptide.

[0266] Preferred pharma-ceutically acceptable carriers include aqueous carriers or diluents. Examples of suitable aqueous carriers that can be used in the compositions of the present invention include water, buffered water, and saline. Examples of other carriers include ethanol, polyols (such as glycerol, propylene glycol, polyethylene glycol, etc.), and suitable mixtures thereof, vegetable oils such as olive oil, and injectable organic esters such as ethyl oleate. Proper fluidity can be maintained, for example, by using coating materials such as lecithin, maintaining the required particle size in the case of dispersion, and using surfactants. In many cases, it is preferable to include an isotonic agent, for example, sugar, polyalcohols such as mannitol, sorbitol, or sodium chloride in the composition.

[0267] The compositions of the present invention may also contain pharma- ceutically acceptable antioxidants. These compositions may contain adjuvants such as preservatives, wetting agents, emulsifiers, and dispersing agents. Prevention of the presence of microorganisms can be ensured by both sterilization procedures (see above) and the inclusion of various antibacterial and antifungal agents, such as parabens, chlorobutanol, phenol sorbic acid, and the like. It may also be desirable to include isotonic agents in the compositions, such as sugars, sodium chloride, and the like. In addition, prolonged absorption of the injectable dosage form can be achieved by including agents that delay absorption, such as aluminum monostearate and gelatin.

[0268] Therapeutic compositions typically must be sterile and stable under the conditions of manufacture and storage. The composition may be formulated as a solution, microemulsion, liposome, or other ordered structure suitable to high drug concentration.

[0269] Sterile injectable solutions can be prepared by incorporating the required amount of active agent (e.g., polypeptide) into a suitable solvent containing one or a combination of the above-listed ingredients as needed, followed by sterile filtration. Generally, dispersions are prepared by incorporating active agent into a sterile vehicle that contains a basic dispersion medium and other ingredients required from those listed above. In the case of sterile powders for preparing sterile injectable solutions, the preferred preparation method is high vacuum drying and freeze-drying (lyophilization), which obtains a powder of active agent and any additional desired ingredients from its previously sterile-filtered solution.

[0270] Particularly preferred compositions are formulated for systemic or local administration. Local administration may be at the site of the tumor or to a tumor-draining lymph node. The composition may be formulated for sustained release, preferably over a period of time. Thus, the composition may be provided in or as part of a matrix that facilitates sustained release. A preferred sustained release matrix may comprise nanoparticles of Montanide or gamma-polyglutamic acid (PGA). Local release of the polypeptide of the invention, optionally over a sustained period of time, may reduce potential autoimmune side effects associated with administration of CTLA-4 antagonists.

[0271] The compositions of the invention may contain additional active ingredients as well as polypeptides of the invention. As described above, the compositions of the invention may contain one or more polypeptides of the invention. They may also contain additional therapeutic or prophylactic agents.

[0272] Also within the scope of the invention is a kit comprising a polypeptide or other composition of the invention and instructions for use. The kit may further comprise one or more additional reagents, such as additional therapeutic or prophylactic agents as described above.

[0273] The polypeptides according to the invention can be used for treatment or prevention. In treatment applications, the polypeptides or compositions are administered to a subject already suffering from a disorder or condition in an amount sufficient to cure, alleviate or partially arrest the pathology or one or more of its symptoms. Such therapeutic treatment may result in a decrease in the severity of disease symptoms or an increase in the frequency or duration of symptom-free periods. An amount adequate to achieve this is defined as a "therapeutically effective amount". In prophylactic applications, the polypeptides or compositions are administered to a subject not yet exhibiting symptoms of the disorder or condition in an amount sufficient to prevent or delay the onset of symptoms. Such an amount is defined as a "prophylactically effective amount". The subject may be identified as being at risk for developing the disease or condition by any suitable means.

[0274] In particular, the polypeptides of the present invention may be useful for the treatment or prevention of cancer. Thus, the present invention provides the polypeptides of the present invention for use in the treatment or prevention of cancer. The present invention also provides a method for treating or preventing cancer, comprising administering to an individual the polypeptides of the present invention. The present invention also provides the polypeptides of the present invention for use in the manufacture of a medicament for the treatment or prevention of cancer.

[0275] The cancer can be prostate cancer, breast cancer, colon cancer, pancreatic cancer, ovarian cancer, lung cancer, cervical cancer, rhabdomyosarcoma, neuroblastoma, multiple myeloma, leukemia, acute lymphoblastic leukemia, melanoma, bladder cancer, gastric cancer, head and neck cancer, liver cancer, skin cancer, lymphoma, or glioblastoma.

[0276] The polypeptide of the present invention or a composition comprising said polypeptide may be administered via one or more routes of administration using one or more of a variety of methods known in the art. As will be appreciated by those skilled in the art, the route and / or mode of administration will vary depending on the desired results. Systemic or local administration is preferred. Local administration may be to the site of a tumor or to a tumor-draining lymph node. Preferred modes of administration for the polypeptide or composition of the present invention include intravenous, intramuscular, intradermal, intraperitoneal, subcutaneous, spinal, or other parenteral modes of administration, for example, by injection or infusion. The phrase "parenteral administration" as used herein refers to modes of administration other than enteral and topical administration, usually by injection. Alternatively, the polypeptide or composition of the present invention may be administered via non-parenteral modes of administration, such as topical, epidermal, or mucosal modes of administration.

[0277] The appropriate dosage of the polypeptide of the present invention can be determined by a skilled physician. The actual dosage level of the active ingredient in the pharmaceutical composition of the present invention can be varied to obtain an amount of the active ingredient that is effective for achieving the desired therapeutic response for a particular patient, composition, and mode of administration, and is not harmful to the patient. The dosage level selected will depend on various pharmacokinetic factors, including the activity of the particular polypeptide used, the route of administration, the time of administration, the rate of excretion of the polypeptide, the duration of treatment, other drugs, compounds and / or materials used in combination with the particular composition used, the age, sex, weight, condition, general health and previous medical history of the patient being treated, and similar factors well known in the pharmaceutical arts.

[0278] A suitable dose of a polypeptide or composition of the invention can be, for example, in the range of about 0.1 μg / kg to about 100 mg / kg of body weight of the patient to be treated. For example, a suitable dose can be about 1 μg / kg to about 10 mg / kg of body weight per day, or about 10 g / kg to about 5 mg / kg of body weight per day.

[0279] Dosage regimen may be adjusted to provide the optimum desired response (e.g., therapeutic response). For example, a single bolus may be administered, or several divided doses may be administered over time, or the dose may be proportionally reduced or increased as indicated by the exigencies of the therapeutic situation. For ease of administration and uniformity of dosage, it is particularly advantageous to formulate parenteral compositions in unit dosage form. Unit dosage form as used herein refers to physically discrete units suitable as unitary doses for subjects to be treated, each unit containing a predetermined amount of active compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier.

[0280] The polypeptide or composition may be administered in a single dose or multiple doses. Multiple doses may be administered via the same or different routes and to the same or different locations. Alternatively, the polypeptide or composition may be administered as a sustained release formulation as described above, in which case less frequent administration is required. The dosage and frequency may vary depending on the half-life of the polypeptide in the patient and the desired duration of treatment. The dosage and frequency of administration may also vary depending on whether the treatment is preventive or therapeutic. In preventive applications, relatively low dosages may be administered at relatively irregular intervals over an extended period of time. In therapeutic applications, relatively high dosages may be administered, for example, until the patient shows partial or complete improvement of the symptoms of the disease.

[0281] The co-administration of two or more agents can be achieved in a number of different ways. In one embodiment, the polypeptide and the other agent can be administered together in a single composition. In another embodiment, the polypeptide and the other agent can be administered in separate compositions as part of a combination therapy. For example, the modulator can be administered before, after, or simultaneously with the other agent.

[0282] The polypeptide or composition of the invention may also be used in a method of increasing the activation of a cell population expressing a first and a second antigen, the method comprising administering to said cell population a polypeptide or composition of the invention under conditions suitable to allow interaction between said cells and the polypeptide of the invention. The cell population typically comprises at least some cells expressing the first antigen and at least some cells expressing the second antigen. The method is typically carried out ex vivo.

[0283] Additionally, as used in this specification and the appended claims, the singular forms "a," "an," and "the" include plural references unless the context clearly indicates otherwise. Thus, for example, reference to "an antibody" includes "antibodies," reference to "an antigen" includes two or more such antigens, reference to "a subject" includes two or more such subjects, etc.

[0284] All publications, patents, and patent applications cited herein, whether supra or infra, are hereby incorporated by reference in their entirety.

[0285] The listing or discussion of an apparently prior-published document in this specification should not necessarily be taken as an acknowledgement that the document is part of the state of the art or is common general knowledge.

[0286] The present invention is further illustrated by the following examples, which should not be construed as further limiting. The contents of all figures and all references, patents and published patent applications cited throughout this application are expressly incorporated herein by reference.

[0287] Preferred, non-limiting examples embodying certain aspects of the present invention will now be described with reference to the following drawings. [Brief description of the drawings]

[0288] [Figure 1] Dual ELISA of single mutant bsAb variants. In panels A-D, mutants evaluated to reduce in silico predicted MHC class II binding of peptides with the S114A mutation are shown, and in panels E-H, mutants evaluated to reduce in silico predicted MHC class II binding of peptides with the T187E mutation are shown. Wild type bsAb AC_05293 was included as a reference. [Diagram 2] Duplex ELISA of double mutant bsAb variants with reduced predicted MHC class II binding of peptides compared to bsAbs with S114A mutation in the constant light chain and / or T187E mutation in the CH1 constant heavy chain. As a reference, WT bsAb, AC_05293, was included. [Diagram 3] Melting temperatures (Tm1) and aggregation temperatures (Tagg) of the different double mutant bsAb variants. As a reference, the WT bsAb, AC_05293, was included. [Figure 4] Aggregation (% HMW) after 1, 2, and 4 weeks of incubation at 40° C. compared to before incubation. Values ​​measured using SEC-HPLC. [Diagram 5] Freeze / thaw stability evaluation. Aggregation, measured as the change in % HMW, was examined after one and three freeze / thaw cycles. [Figure 6] Shear stress stability assessment for all variants. A280 measurements were performed followed by incubation in the MixMate at 2000 rpm for 30 min, followed by centrifugation at 3000xg for 10 min before re-measurement of A280. [Figure 7] Colloidal stability measured as % PEG required to obtain 50% protein precipitation. All variants required PEG concentrations >8-9% indicating high colloidal stability. [Figure 8] Antigen binding of RUBY™ bsAb as determined by dual target ELISA. Simultaneous binding of parental bsAbs AC_05332 (A), AC_05330 (B), AC_5302 (C) and their variants to 5T4 and CD40. [Figure 9] Binding by AC_05332 (A), AC_05330 (B), AC_5302 (C) and their variants to 5T4 expressed on CHO cells (CHO-5T4) and CHO wt cells as determined using flow cytometry. [Figure 10] Binding by AC_05332 (A), AC_05330 (B), AC_5302 (C) and their variants to CD40 expressed on B16 cells (B16-CD40) and B16wt cells as determined using flow cytometry. [Figure 11] This shows an exemplary composition of a bispecific antibody construct, referred to in the RUBY™ format. The bispecific antibody in this figure consists of three polypeptide chains: (1) an IgG heavy chain (white) fused to a Fab light chain via a polypeptide linker. (2) an IgG light chain (brick pattern), and (3) a Fab heavy chain (black). Mutations are introduced at the interface between the heavy and light chains. [Figure 12] CD40xTAA bsAb mediates tumor debris localization to antigen-presenting cells. The number of CEA+ tumor debris clustering with CD40+ cells was quantified after 8 hours of culture using live cell imaging software. Graph shows the mean (+SD) of duplicate wells in one representative experiment out of four (CEA). [Figure 13] Dissociated cells from human colon cancer tumors were analyzed for (left) their CEA expression (gating on total viable cells), (center) their ability to provide cross-linking to CD40xCEA Neo-X-Prime bsAb in a CD40 reporter assay, and (right) upregulation of CD83 following stimulation of tumor-infiltrating immune cells (gating on viable CD45+CD3-CD56- cells) with CD40xCEA Neo-X-Prime bsAb or isotypexCD40 bsAb (data from one representative experiment of three). [Figure 14]Simultaneous binding of CD40 and CEA by CD40xCEA bsAb mediates activation of tonsillar cancer APCs in vitro. Human CD45+HLA-DR+ CD3- cells from tonsillar cancer biopsies were co-cultured with UV-irradiated CHO cells transfected with human CEA in the presence of CD40xCEA bsAb, CD40 mAb, or isotype control. After 13 hours of culture, cells were harvested and the frequency of CD86+CD40+ cells was examined using flow cytometry for CD19+CD20+B cells, CD14+macrophages, CD1c+cDC2s, and XCR1+cDC1s. [Figure 15] MC38-CEACAM5 2 tumor growth and survival. hCD40tg mice inoculated with MC38-CEACAM5 2 tumors were administered the indicated treatments on days 7, 10, and 13 after inoculation. Tumors were measured frequently. The graph shows the mean tumor volume (+SD) of each group until the first mouse in any treatment group reached a tumor volume exceeding the ethical limit, and the percentage of surviving mice in each treatment group. [Figure 16] Dissociated cells from human gastric cancer tumors were analyzed for (left) their CEA expression (gating on total viable cells), (center) their ability to provide cross-linking to CD40xCEA Neo-X-Prime bsAb (ffAC_05337) in a CD40 reporter assay, and (right, 1 nM CD40xCEA) upregulation of CD83 following stimulation of tumor-infiltrating immune cells (gating on viable CD45+CD3-CD56- cells) with CD40xCEA Neo-X-Prime bsAb or isotypexCD40 bsAb (data from one representative experiment of four). [Figure 17] Effect of bispecific antibody ffAC_05337 on CD40 reporter cells when co-cultured with tumor cells at different CEA receptor densities in the presence and absence of soluble CEA. MKN45, CEA high expressing cells (A), LS174T, CEA medium expressing cells (B), HT29 and LOVO, CEA low expressing cells (C-D). Responses were calculated as fold induction over background. [Figure 18]Effect of bispecific antibody ffAC_05337 on CEA-expressing CHO cells and CD40 reporter cells co-cultured with titrated antibodies in the presence or absence of soluble CEA. Responses were calculated as fold induction over background. EXAMPLES

[0289] Example 1 - Identification of in silico predicted mutations that reduce MHC class II binding. Single mutant studies. Objectives and Background The objective of this study was to identify and evaluate mutations (with an S114A mutation in the constant light chain and / or a T187E mutation in the CH1 constant heavy domain - the so-called "primary" mutations described herein) that can eliminate the predicted MHC class II binding of a core peptide in a bispecific antibody (bsAb) without adversely affecting manufacturability or target binding.

[0290] Materials and Methods Core peptide prediction The core peptide of the selected peptides, including the mutation S114A in the constant light chain and the mutation T187E in the constant heavy chain, was predicted using the NetMHCIIpan 3.4 tool. The 20 most common alleles in the world average population, defined by the AbEpiAnalyzer tool (EIR Sciences), were used for prediction with default software settings.

[0291] Design of mutant variants with potential for reduced MCH II binding Based on the identified core peptide, a large set of mutant peptides was designed to cover the S114A and T187E mutations: all 20 amino acids were introduced at contact residues 1, 4, 6, and 9 of the core peptide encompassing the T187E mutation, and at positions 1, 4, and 6 of the core peptide encompassing the S114A mutation (S114 could not be changed since it is at position 9 of the core peptide).

[0292] In silico peptide-MHC class II binding prediction tool In silico predictions were made by providing amino acid sequences to the AbEpiAnalyzer tool. Briefly, for each 15mer peptide in the provided sequence, a percentile rank is generated by comparing the predicted affinity to a large set of randomly selected 15mers. A rank threshold is preferred over affinity because different alleles show bias towards higher or lower binding affinity. As recommended by the IEDB, peptides with a percentile rank of <10 were included in the binding prediction. AbEpiAnalyzer analyzes the potential immunogenicity of antibodies and sequence-modified proteins by first predicting the binding of each 15mer peptide to a large panel of human MHC class II alleles using the NetMHCII3.1 algorithm, and then calculates a position-specific risk score. The score reflects the frequency of HLA-DR, HLA-DP, and HLA-DQ binding subpeptides that overlap with a given position in a defined population. The position-specific risk scores are summed over each sequence. The cutoff value for the location-specific risk score is set to 0.1 (ie, all location-specific risk scores <0.1 are set to 0).

[0293] For antibody analysis, the program uses blastp to identify and align germline genes from a database of heavy and light chain V genes. Complementarity determining regions (CDRs) are identified by using the developed light and heavy chain hidden Markov models based on multiple alignments of heavy and light chains, respectively. For sequence modified proteins, the wild type sequence is provided separately by the user. Potential T cell neoepitopes are identified by subtracting the HLA binding properties of germline or wild type proteins.

[0294] World average populations of HLA alleles were used, where the population percentages are 52.7% North American, 25.3% European, 9.2% North East Asian, 5.9% Southeast Asian, 1.7% Latin American, 1.3% Oceanian, 1.3% West Asian, 1.0% Sub-Saharan African, 0.7% South Asian, 0.6% North African, and 0.1% Australian. Results are presented as location-specific risk scores and as heat plots for identification of allele binding and the presence of frequent (i.e., promiscuous) neoepitopes.

[0295] Amino acid sequence Single mutants were generated using the RUBY™ bsAb AC_05293 as the protein scaffold. In addition to potential deimmunizing mutations, this antibody has a series of RUBY™-specific mutations (Table 1). [Table 11]

[0296] Structure Review The three-dimensional structure of the antibody CH1 and Cκ was performed using PyMOL (version 1.8.2.0) and the antibody structures 5I18 and 3ZHK downloaded from the RCSB protein data bank.

[0297] Gene synthesis and cloning Gene fragments incorporating the identified deimmunizing mutations of interest were obtained from Twist Bioscience and cloned into Alligator's pCDNA3.4 expression vector along with gene fragments encoding additional portions of bsAb AC_05293 using standard type IIS cloning.

[0298] Protein production and purification Antibodies were expressed using transient Expi293 (Life technologies) cultures according to the manufacturer's instructions. Purification of supernatants was performed in Predictor MabSelectSure 50 μl 96-well plates (GE Healthcare). Cells were transfected with three different vectors separately encoding each of the three co-expressed polypeptide chains that make up the bsAb.

[0299] double ELISA Plates were coated with 0.5 μg / mL CD40 in PBS overnight at 4°C. After washing with PBS / 0.05% Tween 20 (PBST), plates were blocked with PBS / 2% BSA for at least 30 min and then washed again. Samples serially diluted in PBS / 0.5% BSA were then added and allowed to bind for at least 1 h at room temperature. After washing, plates were incubated with 0.5 μg / mL biotinylated EpCAM for at least 1 h at room temperature. The double complexed bsAb with CD40 and EpCAM was detected with HRP-labeled streptavidin. SuperSignal Pico Luminescent was used as substrate and luminescence signal was measured using a Fluostar Optima.

[0300] Results and Conclusions Identification of the core peptide Using in silico predictions, it was possible to identify mutations that could lead to peptides with increased MHC II binding. These were peptides encompassing the mutations S114A in the light chain of the added Fab and T187E in the heavy chain of the added Fab. Furthermore, the in silico analysis allowed the identification of amino acids on the predicted MHC II peptides that are likely to be core amino acids (i.e., involved in interactions with either the MHC II complex or the T cell receptor (TCR)) and from this, residues likely to interact with the MHC class II complex (positions 1, 4, 6, and 9 of the core peptide). In Table 2, the core amino acids predicted to contact the MHC class II complex are marked with an X. [Table 12] [ka] , the CKappa domain is underlined and the VL is in bold.

[0301] Identification of deimmunized RUBY variants Using the predicted core amino acids, potential variants with lower predicted MHC class II binding were evaluated using in silico MHC class II peptide binding analysis. The results revealed several variants with predicted risk scores of 0 or close to 0, including S114A variant in the light chain of the appended Fab and T187E variant in the heavy chain of the appended Fab.

[0302] A detailed review of each identified mutation that could potentially reduce the immunogenicity of RUBY was performed to remove mutations that introduce amino acids or sites with unfavorable manufacturability properties, as well as mutations that were highly unlikely to generate a functional, stable protein based on their location in the three-dimensional structure. A complete list of the remaining deimmunizing mutations selected for further evaluation can be found in Table 3. [Table 13]

[0303] Evaluation of single-site mutants Cloning and production RUBY variants bearing one of the additional mutations listed in Table 3 were engineered and produced in a high-throughput 96-well format (HT production). Productivities from transient cultures of the mutant variants were generally good, with levels comparable to the wild-type bsAb (data not shown).

[0304] double ELISA Simultaneous binding to both targets (CD40 and EpCAM) was assessed using a dual ELISA setup. As can be seen in Figure 1, the majority of the mutants evaluated retained binding to both targets at levels comparable to the wild-type bsAb. The dual ELISA results were further confirmed by single ELISAs against both targets (data not shown).

[0305] Overall, it can be concluded that a diverse set of single amino acid mutations could be identified that reduced the in silico predicted immunogenicity risk of RUBY™ bsAb-derived peptides with mutations S114A or T187E without adversely affecting manufacturability or target binding.

[0306] Example 2 - Evaluation of in silico predicted combinations of mutations that reduce MHC class II binding - Double mutant studies. Objectives and Background The objective of this study was to evaluate combinations of mutations that reduce in silico predicted MHC class II binding and to identify pairs of mutations that can reduce the predicted MHC class II binding of the core peptide in RUBY™ bsAb (with an S114A mutation in the constant light domain and / or a T187E mutation in the CH1 constant heavy domain) without adversely affecting antigen binding, stability, or developability.

[0307] Materials and Methods Structure Review The three-dimensional structure of the antibody CH1 and Cκ was performed using PyMOL (version 1.8.2.0) and the antibody structures 5I18 and 3ZHK downloaded from the RCSB protein data bank.

[0308] Amino acid sequence Double mutants were generated using AC_05293 bsAb as the protein scaffold. In addition to potential deimmunizing mutations, this antibody has a series of RUBY™ specific mutations (Table 4). All 20 possible double mutant combinations of Set A and Set B mutations listed in Table 5 were generated. [Table 14]

[0309] Gene synthesis and cloning Gene fragments incorporating the identified deimmunizing mutations of interest were obtained from Twist Bioscience and cloned into Alligator's pCDNA3.4 expression vector along with gene fragments encoding additional portions of bsAb AC_05293 using standard type IIS cloning.

[0310] Protein production and purification Antibodies were expressed using transient Expi293 (Life technologies) cultures in different volumes (high throughput 1.2 mL or 30 mL) according to the manufacturer's instructions. Purification of supernatants from 30 mL cultures was performed on protein A using the NGC system (BioRad) or Predictor MabSelectSure 50 μl 96-well plates (GE Healthcare) for supernatants from high throughput expression. Cells were transfected with three different vectors separately encoding each of the three co-expressed polypeptide chains that make up the bsAb.

[0311] SEC-HPLC Aggregation was measured by SE-HPLC on a 1260 Infinity II system (Agilent Technologies) using a TSK gel Super SW mAB HTP 4 μm, 4.6 × 150 mm column (TOSOH Bioscience) and 100 mM sodium phosphate, pH 6.8, 300 mM NaCl as the mobile phase at ambient temperature and a flow rate of 0.35 ml / min.

[0312] LabCHIP Analysis of all samples was performed on a LabChip GXII (PerkinElmer) according to the manufacturer's instructions and in accordance with our routine guidelines DOCID-371837740-15. Briefly, 2 μL of each protein sample (reduced or non-reduced) was denatured at 90 °C for 5 min, centrifuged, and loaded into the microfluidic chip.

[0313] Single ELISA Plates were coated with either CD40 or EpCAM at 0.5 μg / mL in PBS overnight at 4°C. After washing with PBS / 0.05% Tween 20 (PBST), plates were blocked with PBS / 2% BSA for at least 30 minutes and then washed again. Samples, serially diluted in PBS / 0.5% BSA, were then added and allowed to bind for at least 1 hour at room temperature. After washing, plates were incubated with a secondary anti-kappa antibody at room temperature for at least 1 hour. After washing, luminescent signals were measured using a Fluostar Optima using SuperSignal Pico Luminescent as substrate.

[0314] double ELISA Plates were coated with 0.5 μg / mL CD40 in PBS overnight at 4°C. After washing with PBS / 0.05% Tween 20 (PBST), plates were blocked with PBS / 2% BSA for at least 30 min and then washed again. Samples serially diluted in PBS / 0.5% BSA were then added and allowed to bind for at least 1 h at room temperature. After washing, plates were incubated with 0.5 μg / mL biotinylated EpCAM for at least 1 h at room temperature. The double complexed bsAb with CD40 and EpCAM was detected with HRP-labeled streptavidin. SuperSignal Pico Luminescent was used as substrate and luminescence signal was measured using a Fluostar Optima.

[0315] Octet Kinetic measurements were performed using the Octet RED96 platform (ForteBIo). Biotinylated antigens were coupled to streptavidin sensors (ForteBio) at antigen concentrations of 0.25 μg / mL CD40 or 0.5 μg / mL EpCAM. Antibodies were serially diluted in 1× Kinetic buffer (ForteBio) at starting concentrations of 10 nM CD40 or 25 nM EpCAM and analyzed for binding to the antigen-bound sensors. Association was followed for 300 s followed by dissociation for 300 s in 1× Kinetic buffer. The sensor chip was regenerated using 10 mM glycine, pH 1.7. Data generated were referenced by subtraction of a parallel buffer blank, baseline aligned to the y-axis, step-to-step correlation by alignment to dissociation was performed, and data were smoothed by Savitzky-Golay filtering in the data analysis software (v.9.0.0.14). As a measure of fitting accuracy, processed data were fitted using a 1:1 Langmuir binding model of X2.

[0316] thermal stability Melting temperature (Tm1) and aggregation temperature (Tagg) were measured with the UNCle system (UNchained labs). Intrinsic fluorescence was measured with a linear temperature increase from 20° C. to 95° C. at a rate of 0.4° C. / min. Data analysis was performed using UNcle Analysis software version 2.0 using default settings.

[0317] stability Samples in non-optimized buffer (PBS) were incubated at 2-8 °C and 40 °C for 1, 2, and 4 weeks or subjected to three cycles of freeze-thaw (24, 48, and 72 h). Visual inspection was performed and proteolysis was measured using SE-HPLC, LabChip, and dual ELISA.

[0318] Shear Stress Stability Triplicate samples were subjected to shear stress in a 96-well plate shaker MixMate (Eppendorf) with vigorous agitation at 2000 rpm for 30 min. Protein precipitates were removed by centrifugation at 3000 g for 10 min and absorbance at 280 nm was measured using a BigLunatic.

[0319] Colloidal stability Samples were mixed with PBS / PEG solutions with different PEG concentrations ranging from 4% to 36%, added in duplicate to a 96-well filter plate and incubated overnight at room temperature. The filtrates obtained by centrifugation at 12000g for 15 min were collected and the absorbance at 280 nm (to determine protein loss) was measured using a BigLunatic and compared to controls.

[0320] Results and Conclusions Selection of mutations to combine into novel deimmunized RUBY variants Based on the highly encouraging results from the generation of single-site mutants and ELISA evaluation, a set of promising mutations was selected for each risk site after considering the three-dimensional structures surrounding these sites. Taking into account biophysical properties such as hydrophobicity, charge, and size, as well as possible beneficial / detrimental interactions with the side chains of the surrounding amino acids, the selected set of mutants is listed in Table 5. [Table 15]

[0321] manufacturability BsAb double mutants were generated from transient cultures. Expi293 expression was performed in 30 mL cultures. Expression yields were calculated using A280 measurements determined by BigLunatic after MabSelectSure purification. SEC-HPLC analysis was performed to confirm protein size, aggregation, and fragmentation. In addition, LabCHIP (reducing and non-reducing conditions) was performed to further evaluate aggregation and fragmentation. 16 of the 20 variants had yields over 100 mg / L (Table 6) and purity over 98%. Overall, good yields and purity comparable to wild-type bsAb were obtained. [Table 16]

[0322] double ELISA Single and double ELISAs were performed to evaluate the binding of the different double mutant variants to their targets. Single ELISA data showed good binding to their single targets (CD40 or EpCAM) for all variants (data not shown). A similar trend was observed in the double ELISA, except for variants AM_4115-4126 and AM_4115-4131 (Figure 2), which showed reduced binding.

[0323] Octet The binding affinity of all variants was determined using Octet (Pall ForteBio). Biotinylated antigen (CD40 or EpCAM) was immobilized on a streptavidin biosensor and binding to variants and wild-type bsAb in solution was measured. Similar KDs were observed for binding of all variants and wild-type bsAb to CD40. All variants showed a similar trend of slightly higher KD when bound to EpCAM, except for the I126S mutation (ID number 4115) (Table 7). The reduced EpCAM affinity for the I126S variant is consistent with the results obtained by ELISA (Figure 2). [Table 17]

[0324] stability To assess the stability of the variants, melting temperature (Tm), shear stress, colloidal stability, and storage stability at different temperatures were evaluated.

[0325] thermal stability To determine the melting (Tm1) and aggregation temperatures (Tagg) of the variants, analyses were performed using an UNcle instrument (UNchained Biolabs). Variants with mutations I126A (4109), I126G (4110), and I126S (4115) had slightly reduced Tm1 (below 65 °C) compared to the wt bsAb, whereas the T109P (4117) and A111V (4120) variants had Tm1 below 65 °C (Figure 3). On the other hand, the aggregation temperatures were very similar for all bsAb double mutants and comparable to the WT bsAb (i.e., around 75 °C ± 1-2 °C).

[0326] High temperature and freeze / thaw stability High temperature stability was performed by incubating the proteins at 40°C for up to 4 weeks. After 4 weeks of incubation, LabCHIP and dual ELISA analysis was performed on all samples, and SEC-HPLC analysis was performed on samples at weeks 1, 2, and 4. Freeze-thaw stability was assessed by incubating the proteins at -80°C and thawing after 24, 48, and 72 hours in a water bath set at 37°C. SEC-HPLC analysis was performed only on samples thawed after 24 and 72 hours. In addition, all samples were visually inspected for any particles at each of the three time points. Minimal aggregation (<3% change in HMW) was observed for all variants after storage at 40°C, even after 4 weeks of incubation, indicating very high temperature stability for all double mutants (Figure 4). Compared to the WT bsAb, slight aggregation after three freeze / thaw cycles was observed for I126A (4109) and I126G (4110). Surprisingly, all mutants with I126S (4115), T109P (4117), and A111V (4120) showed improved freeze / thaw compared to the WT bsAb (Figure 5). This indicates that the mutations not only result in the potential predicted reduction in MHCII binding, but also improve stability.

[0327] Shear stress Assessment of the ability of all variants to withstand shear stress degradation was performed using Alligator's in-house developed shear stress assay. The assay is based on agitation at a given shaking speed and time. The amount of protein loss is determined by calculating the change in A280 before and after agitation. All variants were shown to be highly shear stress stable, as the difference between protein concentrations before and after agitation was small (Figure 6). Overall, for all constructs, protein loss due to agitation was less than 10%.

[0328] Colloidal stability The variants were further evaluated for colloidal stability using a PEG precipitation assay. The addition of different concentrations of PEG to a protein solution leads to precipitation as a result of the excluded volume effect. PEG, being a long chain polymer, takes up more space in solution than a protein of similar molecular weight, thus reducing the solubility of the protein and leading to protein precipitation. The assay provides a relative measurement of colloidal stability, measured as the concentration of PEG required to precipitate 50% of the protein amount in the sample. The higher the PEG concentration, the higher the colloidal stability. Values ​​are compared to a control that is considered to have high colloidal stability and is known to require 8-9% PEG to obtain 50% protein precipitation. All double mutant variants showed comparable colloidal stability to the WT bsAb and performed better than the control (Figure 7).

[0329] Overall, several of the double variants tested showed generally good binding, stability, and manufacturability in transient culture. The mutations I126S, T109P, A111V in the constant light chain and the mutations S183T and V188G in the constant heavy domain CH1 were particularly beneficial with respect to stability, with the combination of the mutations T109P, A111V in the constant light chain and the mutations S183T and V188G in the constant heavy domain CH1 resulting in generally good target binding, high thermal stability, colloidal stability, and generally high stress stability (including stresses such as high temperature, freeze / thaw, and shear stress).

[0330] Example 3 - Identification of MHC class II binding peptides using MHC-associated peptide proteomics (MAPP) assay the purpose The aim of this study is to identify non-self peptides derived from RUBY™ bispecific antibodies (bsAbs) with and without optimization of the mutations S183T in CH1 of chain H2 and T109P in CKappa of chain H1, which are naturally processed by antigen presenting cells and presented to MHC class II. Such non-self peptides presented to MHC class II have the potential to induce immunogenic responses and the induction of undesired anti-drug antibodies. Therefore, a reduction in the number of such peptides in protein drugs such as bispecific antibodies would be beneficial and may lead to a better safety profile in the clinical environment.

[0331] Materials and Methods Table 8 describes the two RUBY™ bsAbs included in the assay and the set of optimized mutations included. In addition to the mutations listed in Table 8, both RUBY™ bsAbs have the mutations Q44R in the variable heavy (VH) and variable light (VL) domains of chain H1, and Q44E in the VL domain of chain L1 and Q44E in the VH of chain H2. However, only the RUBY™ specific mutations incorporated into the constant domains of the bsAbs are considered in this evaluation, as any peptide that incorporates a variable domain mutation is likely influenced by the specific amino acid sequence of that particular variable domain and is not an inherent feature of the RUBY™ bsAb format. [Table 18]

[0332] Briefly, monocyte-derived dendritic cells (MoDCs) were derived from a cohort of 10 healthy donors (HLA typing available in Table 8) and incubated with the test samples. MoDCs were then lysed, HLA-DR / peptide complexes immunocaptured, and peptides eluted and sequenced by mass spectrometry (MS). Analysis of the MS data identified peptides that were unique to individual donors and common across multiple donors. The identified peptides were further analyzed to exclude self-peptide sequences from the final data set. Self-peptide sequences are unlikely to contain T cell epitopes capable of inducing anti-drug antibody (ADA) responses, either due to thymic selection or peripheral T cell tolerance. [Table 19]

[0333] In addition, in silico analysis of all identified non-self peptides was performed using the iTope-AI algorithm (Abzena Ltd) to predict binding to the 46 most common MHC class II alleles. A "positional risk score" was calculated, representing the sum of predicted binding to each allotype.

[0334] Results and Conclusions Tables 10 and 11 summarize the results from the MAPP assay and in silico prediction for AC_05293 and Multi46. In general, the number of identified peptides generated by RUBY™-specific mutations was low, with the frequency of donors presenting such peptides being 30% or less. In the case of AC_05293, no peptides were identified in any donor encompassing mutations H168A or H170G in CH1 of H1 chain, or mutation L135Y in CKappa of L1 chain. A variable number of peptides including mutations S114A and N137L in CKappa of chain H1, T187E in CH1 of H2, and S176W in CKappa of L1 were identified in one to three donors, with the total positional risk score of these peptides ranging from 4 to 81 (total bsAb positional risk score = 122). Although no new peptide clusters were identified in the analysis of Multi46, the introduction of the optimization mutations T109P in CKappa of chain H1 and S183T in CH1 of chain H2 reduced both the number of identified peptides and the total position risk score. After the introduction of the optimization mutation T109P, no peptides covering the RUBY™-specific mutation S114A in CKappa of H1 were identified in any of the 10 donors in the analysis of AC_05293, compared with two peptides covering this mutation identified in two donors. The introduction of the optimization mutation S183T did not reduce the number of presented peptides covering the mutation T187E in CH1 of chain H2, but the frequency of donors presenting such peptides decreased from 3 to 2, and the total position risk score of these peptides decreased from 12 to 8. Overall, the introduction of the two optimization mutations in CKappa of chain H1 and CH1 of chain H2 dramatically reduced the sum of the bsAb position risk scores from 122 to 37. [Table 20-1] [Table 20-2] [Table 21-1] [Table 21-2]

[0335] Overall, MAPP and in silico predictions performed on two RUBY™ bsAbs with and without the optimization of the mutations T109P in CKappa of the H1 chain and S183T in CH1 of the H2 chain clearly demonstrate that the introduction of these mutations reduced the total number of peptides presented, the frequency of donors presenting these peptides, as well as the predicted risk score of the presented peptides. Thus, adding such optimization mutations to RUBY™ bsAbs has the potential to reduce the risk of induction of an immunogenic response.

[0336] Example 4 - Mutational strategy to reduce the level of co-purified Fab fragments in the purification process of RUBY™ bispecific antibodies Background and Objectives The complex design of the RUBY™ bispecific antibody (bsAb) format does not allow for the formation of any correctly sized by-products, but the formation of Fab fragments due to mispairing of chain 2 (L1) and chain 3 (H2) is possible. When such soluble Fab fragments have a heavy chain variable (VH) domain derived from the IGHV3 germline gene family, they naturally have a Protein A binding site located in the VH, which allows for the undesired co-purification of such Fab fragments. This Protein A binding site has been identified as a conserved portion of framework regions 1, 3 and CDRH2 of the VH (Bach, Lewis et al. 2015). To further improve the manufacturability of RUBY™, it would be desirable to engineer the molecule such that these undesired Fab products do not have the ability to bind Protein A, thereby inhibiting their ability to co-purify with the correctly sized RUBY™ product.

[0337] The aim of this study was to evaluate a series of mutations (n=3) (see Table 12) that could disrupt the Protein A binding site found in the H2 chain with a VH of IGHV3 origin. The series of mutations were introduced into three different RUBY™ bsAbs with such an IGHV3-origin VH in their H2 chain and evaluated for manufacturability and antigen binding.

[0338] Materials and Methods Production and purification of RUBY™ bsAb A series of RUBY™ bsAbs, listed in Table 12, were expressed along with the three parental bsAbs AC_05332, AC_05330, and AC_05302. All RUBY™ bsAbs included in this study also have a series of format-specific mutations, listed in Table 13. A total of 12 sets of bsAbs were expressed in 30 mL or 60 mL cultures using transient Expi293 HEK (Life Technologies) cells according to the manufacturer's protocol. Purification of the produced RUBY bsAbs was performed on an NGC10 (BioRad) system using MabSelect SuRe, 1 mL, columns (GE Healthcare) according to the manufacturer's protocol. [Table 22] [Table 23]

[0339] Manufacturability assessment After Protein A purification, expression yields were calculated using A280 measurements determined by Lunatic (UNchained Labs). Aggregation and the presence of low molecular weight (MW) contaminants such as soluble Fab fragments were analyzed at ambient temperature and 0.35 ml / min. 6The proteins were measured by SE-HPLC on a 1260 Infinity II system (Agilent Technologies) using a TSK gel Super SW mAB HTP 4 μm, 4.6 × 150 mm column (TOSOH Bioscience) and 100 mM sodium phosphate, pH 6.8, 300 mM NaCl as the mobile phase at a flow rate of 100 μg / ml. Protein quality was assessed using a LabChip GXII Touch electrophoresis system according to the manufacturer's instructions.

[0340] Assessment of antigen binding using dual target ELISA and flow cytometry Antigen binding was assessed by dual target ELISA. Briefly, ELISA plates were coated with 0.5 μg / ml of relevant antigen in PBS overnight at 4°C. After washing with PBS / 0.05% Tween 20 (PBST), plates were blocked with PBST / 2% BSA for at least 30 min and then washed again. Samples serially diluted in PBST / 0.5% BSA were then added and allowed to bind for at least 1 h at room temperature. After washing, plates were incubated with 0.5 μg / mL of biotinylated second antigen for at least 1 h at room temperature. Dual complexed bsAb was detected with HRP-labeled streptavidin. SuperSignal Pico Luminescent was used as substrate and luminescence signal was measured using a Fluostar Optima. Binding between parental and mutant RUBY pairs was compared.

[0341] Binding to each target expressed on cells was assessed using flow cytometry. Briefly, CHO cells modified to express 5T4, B16 cells modified to express CD40, and wild-type CHO and B16 cell lines were incubated with titrated concentrations of RUBY™ bsAb. Antibody binding was detected using a fluorochrome-conjugated anti-human IgG and analyzed using flow cytometry.

[0342] Results and Conclusions Twelve RUBY™ bsAbs were produced at various levels with yields ranging from 14 to 181 mg / L (Table 14). With the exception of AC_05375(T65I) and AC_05376(T65E), both of which were produced significantly lower than the parent variants, only minor differences could be observed between the parent and mutant bsAbs. All variant RUBY™ bsAbs contained significantly lower amounts of low molecular weight species such as Fab fragments compared to their parent bsAbs after Protein A purification. Only minor differences in aggregation levels (HMW species) could be observed between the parent and mutant bsAbs. [Table 24]

[0343] Protein quality and levels of co-purified Fab fragments were then assessed using LabChip analysis. As seen in Table 15, introduction of either the T65E, T65A, or T65I mutations dramatically reduced the levels of co-purified Fab fragments after protein purification. The changes in the levels of intact RUBY™ bsAb (main peak levels, corrected for changes in Fab fragments) induced by the introduction of Protein A site-disrupting mutations were generally small, except for the T65A and T65I mutations into AC_05332, which dramatically affected the quality of the bsAb produced. [Table 25]

[0344] Figure 8 summarizes the results of the dual target ELISA analysis. The simultaneous binding of AC_05332 to both target antigens (5T4 and CD40) was reduced by the introduction of all three evaluated mutations, but to a much lesser extent for T65E (AC_05370) and T65A (AC_05371) than for T65I (AC_05372). These differences between the parent AC_05332 and its mutated variants may be due in part to the reduced protein quality seen especially in the T65A and T65E mutants (see Table 15). The mutations introduced in AC_05374 and AC_05374 abolished the ability of these bsAbs to simultaneously bind both target antigens, whereas the antigen binding capacity of AC_05330 did not appear to be affected by the introduction of the mutation T65E (AC_05373). AC_05302 retained antigen binding even after the introduction of the T65A (AC_05377) and T65I (AC_05378) mutations, but did not retain antigen binding after the introduction of the T65E (AC_05376) mutation.

[0345] To further evaluate the effect of introducing mutations that disrupt the Protein A binding site on target binding to cells expressing the two targets, flow cytometry was used to assess (AC_05371 and AC_05372 were excluded due to suboptimal protein quality). As can be seen in Figure 9, binding to CHO cells expressing 5T4 is not affected by the introduction of mutations in the CD40 binding domain of AC_05332, as would be expected. Binding of AC_05330, AC_05302 and their mutant versions to 5T4 on cells correlates with the results of the dual ELISA described above. However, in this assay, all variants of AC_05302 retain 5T4 binding. Meanwhile, even in this assay, the AC_05330 mutant appears to retain antigen binding only with the T65E mutation. Binding to CHOwt cells that do not express 5T4 is not affected by the introduction of any of the mutations examined.

[0346] As can be seen in Figure 10, binding to CD40-expressing B16 cells for AC_05332 and its T65E variant correlates well with the ELISA results, with only a slight decrease in target binding introduced by the T65E mutation. As expected, all AC_05330 and its mutant variants show similar binding to B16 cells, as no mutations were introduced in the CD40-binding domain of these RUBY™ bsAbs. Apart from the unexpected lack of CD40 binding by AC_05376 (the T65E mutant of AC_05302), AC_05302 and its T65I and T65A mutant versions are also unaffected by the introduction of protein A site-disrupting mutations in the 5T4-binding domain of these bsAbs. Binding to wtB16 cells, which do not express CD40, is not detected for any of the RUBY bsAbs evaluated.

[0347] Importantly, it can be concluded that all three mutations (T65E, T65A, and T65I in the VH of the RUBY™ H2 chain) dramatically reduce the amount of co-purifying Fab fragments in all three bsAbs evaluated in this study, confirming that these mutations indeed disrupt the Protein A binding site in the VH of these molecules. In general, the impact on productivity, amount of aggregates, and protein quality is limited, except for AC_05332, where T65A and T65I significantly affect protein quality. Although the impact on target binding differs between the different mutations introduced in AC_05332, AC_05330, and AC_05302, as assessed using both dual-target ELISA and cell binding by FACS, for all three bsAbs at least one mutation can be identified that significantly reduces the amount of co-purifying Fab fragments while having little or no effect on target binding.

[0348] Overall, these studies demonstrate that the Protein A site-disrupting mutations evaluated effectively reduce the amount of co-purifying Fab fragments during the purification step of the RUBY bsAb. The evaluation also demonstrates that it is possible to introduce such mutations without significantly affecting productivity, protein quality, or target binding.

[0349] Example 5 As shown in Table 16, a CD40xCEACAM5 bispecific antibody was developed to test the optimized RUBY™ mutations in assays of therapeutic efficacy. [Table 26]

[0350] Materials and Methods MB49 CEA-overexpressing cells were labeled with the fluorescent dye PKH26 (Sigma-Aldrich) according to the manufacturer's instructions. The labeled MB49-CEA cells were heat shocked at 45°C for 10 min to induce necrosis, followed by overnight incubation at 37°C. The heat-shocked cells were then centrifuged and the supernatant containing the necrotic tumor cell line debris was collected. Raji cells were labeled with the nuclear dye Hoechst 33342 (Thermo Scientific) and incubated with necrotic debris and titrated antibodies (ffAC_05337 or 1132). Images were captured using a Cytation 5 live cell imager (BioTek) and the number of PKH26-stained tumor debris that colocalized with Hoechst-stained Raji cells was quantified using Gen5 software (BioTek).

[0351] result A dose-dependent increase in clusters of necrotic debris from MB49 tumor cell lines transfected with CEA along with Raji cells was seen upon addition of ffAC_05337 bsAb targeting CD40xCEA, but not monospecific CD40 Ab 1132 (shown in Figure 12).

[0352] Example 6 - Functional assays using cells obtained from primary human colon cancer patients Dissociated primary cells from colon cancer patients were purchased from Discovery Life Sciences (Huntsville, AL). Immediately after thawing, DTCs were counted using a NucleoCounter® NC-200™ (Chemometec, Denmark) and 20,000 viable cells were pipetted into each well. Cancer cells were used to assess function in a CD40 bioassay or, alternatively, to analyze the ability of primary cancer cells to activate immune cells in the same tumor sample. 200,000 viable cells were pipetted into a Nunc UpCell 96-well plate (Thermo Scientific, 174897). ATOR-4066 or control was then added to the wells. The plate was incubated in a 37°C, 5% CO2 incubator for 48 hours. Cells were then harvested and analyzed by flow cytometry. [Table 27]

[0353] result First, it was demonstrated that CEA density in patient-derived tumors was sufficient to provide cross-linking and induce CD40 stimulation using a reporter cell assay. These results demonstrated that patient-derived cancer cells were able to induce cross-linking and CD40 activation similar to cell lines (Figure 13). Second, culturing dissociated cells from patient-derived colon tumors demonstrated that CD40xCEA bsAb (ffAC_05337) was able to activate tumor-infiltrating immune cells (Figure 13).

[0354] Example 7 Materials and Methods Human samples The collection of tonsillar cancer samples at Lund University Hospital was approved by the Swedish Ethical Review Authority ethical review body (reference number 2017 / 580) and participating patients gave written informed consent.

[0355] Cell isolation and co-culture Tonsillar cancer biopsies were cut into small pieces in RPMI1640 medium (ThermoFisher Scientific) supplemented with 0.1 mg / mL gentamicin (Sigma-Aldrich). Tissue fragments were enzymatically digested with collagenase IV (Sigma-Aldrich) (2.0 mg / mL) and DNase I (Sigma Aldrich) (200 K units / mL) for 20 min at 37°C. Cells were filtered using a 70 μm cell strainer (BD Biosciences) and stained with CD3-PerCPCy5.5, VS620-PECF594, CD45-APCH7, and HLA-DR-BV711 for cell sorting using a FACSAria IIu (BD Biosciences). Viable 10 4 6 × 10 CD45+ HLA-DR+ CD3− cells per well 4 Sorting was performed directly into 96-well flat-bottom plates (Nunc UpCell, ThermoFisher Scientific) pre-seeded with UV-irradiated CHO-CEA cells. 19 nM CD40xCEA bsAb, CD40 mAb, or isotype control was added to the co-cultures for 13 h, after which the supernatants were collected and the cells were washed and blocked against non-specific binding with ChromPure mouse IgG (Jackson ImmunoResearch) for 15 min at room temperature. Cells were immediately stained with fluorochrome-conjugated antibodies (Supplementary Table 1) and analyzed by flow cytometry using a FACSAria IIu instrument (BD Biosciences). Cytokine analysis was performed using Bio-Plex Pro human cytokine 17-plex assays on a Bio-PlexR 200 system (Bio-Rad Lab). [Table 28]

[0356] result As shown in FIG. 14, simultaneous binding of CD40 and CEA by CD40×CEA bsAb (ffAC_05337) mediates activation of tonsillar cancer APCs in vitro.

[0357] Example 8: Antitumor effect of CD40-CEACAM5 bispecific antibody ffAC_05337 Background and Objectives ffAC_05337 is a CD40-CEA bispecific antibody in the RUBY™ format. The antibody is LALA mutated to silence Fcg receptor binding.

[0358] The aim of this study was to evaluate the antitumor efficacy of ffAC_05337 and CD40 mAbs in human CD40 transgenic (hCD40tg) mice inoculated with a CEACAM5-transfected murine tumor cell line called MC38-CEACAM5 2.

[0359] Materials and Methods Nine-week-old female hCD40tg mice were injected with 1 × 10 6 MC38-CEACAM5 2 cells (obtained from Kerafast) were inoculated subcutaneously. On days 7, 10, and 13 post-inoculation, mice were administered 100 μg of wild-type CD40 monospecific antibody 1132 or 167 μg of CD40-CEACAM5 bsAb ffAC_05337 intraperitoneally. A group of vehicle-treated mice was also included. Tumor width (w), length (l), and height (h) were measured frequently with calipers and tumor volume was calculated using the following formula: (width / 2×length / 2×height / 2×π×(4 / 3)).

[0360] Results and Conclusions The data showed that treatment with CD40-CEACAM5 bsAb ffAC_05337, but not CD40 mAb 1132, reduced MC38-CEACAM5 tumor volume compared to vehicle-treated mice (Figure 15). Furthermore, treatment with ffAC_05337, but not 1132, resulted in improved survival compared to vehicle-treated mice (Figure 15).

[0361] Example 9 - Functional assays using cells obtained from primary human gastric cancer patients Dissociated primary cells from gastric cancer patients were purchased from Discovery Life Sciences (Huntsville, AL). Immediately after thawing, DTCs were counted using a NucleoCounter® NC-200™ (Chemometec, Denmark) and 20,000 viable cells were pipetted into each well. Cancer cells were used to assess function in a CD40 bioassay or, alternatively, to analyze the ability of primary cancer cells to activate immune cells in the same tumor sample. 200,000 viable cells were pipetted into a Nunc UpCell 96-well plate (Thermo Scientific, 174897). CD40xCEA bsAb (ffAC_05337) or control was then added to the wells. Plates were incubated in a 37°C, 5% CO2 incubator for 48 hours. Cells were then harvested and analyzed by flow cytometry. [Table 29]

[0362] result First, it was demonstrated that CEA density in patient-derived tumors was sufficient to provide cross-linking and induce CD40 stimulation using a reporter cell assay. These results demonstrated that patient-derived cancer cells were able to induce cross-linking and CD40 activation similar to cell lines (Figure 32). Second, culturing dissociated cells from patient-derived gastric tumors demonstrated that CD40xCEA bsAb (ffAC_05337) was able to activate tumor-infiltrating immune cells (Figure 16).

[0363] Example 10 - Evaluation of CD40 agonist function in the presence of soluble CEA using a CD40 reporter assay. Objectives and Background The aim of this study was to evaluate the CD40 agonist function of bispecific antibody ffAC_05337 in the presence of CEA-expressing cells and physiologically relevant concentrations of soluble CEA using a CD40 reporter assay. CD40 cross-linking is mediated by the simultaneous binding of CD40 expressed on CD40 reporter cells and CEA expressed on CHO cells or CEA-expressing human tumor cells. In addition, since high levels of soluble CEA can be detected systemically in cancer patients, agonist function was evaluated in the presence of physiologically relevant concentrations of soluble CEA.

[0364] Materials and Methods The agonist function of ffAC_05337 was assessed using a CD40 reporter assay (Promega, CD40 Bioassay Kit CS JA2155). The assay was performed according to the manufacturer's protocol. Briefly, CD40 reporter cells and titrated concentrations of ffAC_05337 were diluted in RPMI with 10% FCS and added to the assay plate followed by the addition of CEA-transfected CHO, CHO wt, or CEA-expressing human tumor cells. In addition, the assay was performed in the presence of 0.5, 1, 5, 25, or 50 μg / ml soluble CEA. The assay plate was incubated at 37°C for 6 hours before adding Bio-Glo™ Luciferase Assay Detection Solution and analyzing on a BMG ELISA plate reader.

[0365] Results and Conclusions These results show that the bispecific antibody ffAC_05337 induces CD40 activation in the presence of CEA and its potency and efficacy are not affected by the presence of soluble CEA in the culture (Figures 17 and 18). In the presence of 25 and 50 μg / ml of soluble CEA, a slight decrease in the efficacy of ffAC_05337 can be observed (Figure 18).

[0366] Additional sequences relevant to the present invention AC_05293 H1 chain (SEQ ID NO: 261) EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRRAPGKGLEWVSIGSYGGGTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARYVNFGMDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVATG PAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKG QPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLLSPGKGGGGSGGGGSGGGGSELVMTQSPSSLTVTAGEKVTMSCKSSQSLLNSGNQKNYLTWYQRKPGQP PKLLIYWASTRESGVPDRFTGSGSGTDFTLTISSVQAEDLAVYYCQNDYSYPLTFGAGTKLEIKRTVAAPAVFIFPPSDEQLKSGTASVVCLLKNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC H2 chain (SEQ ID NO:262) EVQLLEQSGAELVRPGTSVKISCKASGYAFTNYWLGWVKERPGHGLEWIGDIFPGSGNIHYNEKFKGKATLTADKSSSTAYMQLSSLTFEDSAVYFCARLRNWDEPMDYWG QGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVEVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSC L1 chain (SEQ ID NO: 263) DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQEKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYGRNPPTFGQGTKLEIK RTVAAPSVFIFPPSDEQLKSGTASVVCYLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLWSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC Multi46 H1 chain (SEQ ID NO:264) EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRRAPGKGLEWVSGIGSYGGGTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARYVNFGMDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVAT GPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISK AKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKGGGGSGGGGSGGGGSDIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQRKPGKAPK LLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSSHGPLLTFGQGTKLEIKRPVAAPAVFIFPPSDEQLKSGTASVVCLLKNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC H2 chain (SEQ ID NO:265) QVQLVQSGAEVKKPGSSVKVSCKASGGTFGYYAIHWVREAPGQGLEWMGGIGSIFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARAWSSDHMDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLTSVVEVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSC L1 chain (SEQ ID NO: 266) DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQEKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYGRNPPTFGQGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCYLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLWSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC AC_05332 H1 chain (SEQ ID NO: 267) EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRRAPGKGLEWVSAISGSGGSTYY ADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARYYGGYYSAWMDYWGQGTLVTVS SASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVATGPAVLQS SGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAG GPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQY NSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRD ELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSR WQQGNVFSCSVMHEALHNHYTQKSLSLSPGKGGGGSGGGGSGGGGSDIQMTQSPSSLSAS VGDRVTITCRASQSISSYLNWYQRKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLT ISSLQPEDFATYYCQQYGRNPPTFGQGTKLEIKRTVAAPAVFIFPPSDEQLKSGTASVVC LLKNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYAC EVTHQGLSSPVTKSFNRGEC L1 chain (SEQ ID NO: 268) DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQEKPGKAPKLLIYAASSLQSGVPS RFSGSGSGTDFTLTISSLQPEDFATYYCQQTYGYLHTFGQGTKLEIKRTVAAPSVFIFPP SDEQLKSGTASVVCYLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLWSTLT LSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC H2 chain (SEQ ID NO: 269) EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVREAPGKGLEWVSGIGSYGGGTYY ADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARYVNFGMDYWGQGTLVTVSSAST KGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLY SLSSVVEVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSC AC_05330 H1 chain (SEQ ID NO: 270) EVQLLESGGGLVQPGGSLRLSCAASGFTFSTYGMHWVRRAPGKGLEWLSYISGGSSYIFY ADSVRGRFTISRDNSENALYLQMNSLRAEDTAVYYCARILRGGSGMDLWGQGTLVTVSSA STKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVATGPAVLQSSG LYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGP SVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNS TYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDEL TKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQ QGNVFSCSVMHEALHNHYTQKSLSLSPGKGGGGSGGGGSGGGSDIQMTQSPSSLSASVG DRVTITCRASQSISSYLNWYQRKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTIS SLQPEDFATYYCQQTYGYLHTFGQGTKLEIKRTVAAPAVFIFPPSDEQLKSGTASVVCLL KNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSSTLTLSKADYEKHKVYACEV THQGLSSPVTKSFNRGEC L1 chain (SEQ ID NO: 271) QSVLTQPPSASGTPGQRVTISCTGSSSNIGAGYNVYWYQELPGTAPKLLIYGNINRPSGV PDRFSGSKSGTSASLAISGLRSEDEADYYCAAWDKSISGLVFGGGTKLTVLGQPKAAPSV TLFPPSSEELQANKATLVCYISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAAW SYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS H2 chain (SEQ ID NO: 272) EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVREAPGKGLEWVSAISGSGGSTYY ADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARYYGGYYSAWMDYWGQGTLVTVS SASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQS SGLYSLSSVVEVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSC AC_05302 H1 chain (SEQ ID NO: 273) EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRRAPGKGLEWVSGIGSYGGGTYY ADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARYVNFGMDYWGQGTLVTVSSAST KGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVATGPAVLQSSGLY SLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSV FLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTY RVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTK NQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQG NVFSCSVMHEALHNHYTQKSLSLSPGKGGGGSGGGGSGGGGSDIQMTQSPSSLSASVGDR VTITCRASQSISSYLNWYQRKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSL QPEDFATYYCQQTYGYLHTFGQGTKLEIKRTVAAPAVFIFPPSDEQLKSGTASVVCLLKN FYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTH QGLSSPVTKSFNRGEC L1 chain (SEQ ID NO: 274) DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQEKPGKAPKLLIYAASSLQSGVPS RFSGSGSGTDFTLTISSLQPEDFATYYCQQYGRNPPTFGQGTKLEIKRTVAAPSVFIFPP SDEQLKSGTASVVCYLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLWSTLT LSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC H2 chain (SEQ ID NO: 275) EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVREAPGKGLEWVSAISGSGGSTYY ADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARYYGGYYSAWMDYWGQGTLVTVS SASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQS SGLYSLSSVVEVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSC ffAC_05337 H1 chain (SEQ ID NO:276) EVQLLESGGGLVQPGGSLRLSCAASGTFSSSYMGWVRRAPGKGLEWVSSIGSGSYSTSY ADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARYPSVPFPLHLDYWGQGTLVTVS SASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVATGPAVLQS SGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAG GPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQY NSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRD ELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSR WQQGNVFSCSVMHEALHNHYTQKSLSLSPGKGGGGSGGGGSGGGGSQSVLTQPPSASGTP GQRVTISCTGSSSNIGAGYNVYWYQRLPGTAPKLLIYGNINRPSGVPDRFSGSKSGTSAS LAISGLRSEDEADYYCAAWDKSISGLVFGGGTKLTVLGQPKAAPAVTLFPPSSEELQANK ATLVCLIKDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAAWSYLSLTPEQWKSHR SYSCQVTHEGSTVEKTVAPTECS L1 chain (SEQ ID NO: 277) DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQEKPGKAPKLLIYAASSLQSGVPS RFSGSGSGTDFTLTISSLQPEDFATYYCQQAGNPHTFGQGTKLEIKRTVAAPSVFIFPPS DEQLKSGTASVVCYLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLWSTLTL SKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC H2 chain (SEQ ID NO: 278) EVQLLESGGGLVQPGGSLRLSCAASGFTFSTYGMHWVREAPGKGLEWLSYISGGSSYIFY ADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARILRGGSGMDLWGQGTLVTVSSA STKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSG LYSLTSVVEVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSC AC_05337 (parent of ffAC_05337) H1 chain (SEQ ID NO: 279) EVQLLESGGGLVQPGGSLRLSCAASGFTFSSSYMGWVRRAPGKGLEWVSSIGSGSYSTSY ADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARYPSVPFPLHLDYWGQGTLVTVS SASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVATGPAVLQS SGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAG GPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQY NSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRD ELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSR WQQGNVFSCSVMHEALHNHYTQKSLSLSPGKGGGGSGGGGSGGGGSQSVLTQPPSASGTP GQRVTISCTGSSSNIGAGYNVYWYQRLPGTAPKLLIYGNINRPSGVPDRFSGSKSGTSAS LAISGLRSEDEADYYCAAWDKSISGLVFGGGTKLTVLGQPKAAPAVTLFPPSSEELQANK ATLVCLIKDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAAWSYLSLTPEQWKSHR SYSCQVTHEGSTVEKTVAPTECS L1 chain (SEQ ID NO: 280) DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQEKPGKAPKLLIYAASSLQSGVPS RFSGSGSGTDFTLTISSLQPEDFATYYCQQAGNPHTFGQGTKLEIKRTVAAPSVFIFPPS DEQLKSGTASVVCYLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLWSTLTL SKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC H2 chain (SEQ ID NO: 281) EVQLLESGGGLVQPGGSLRLSCAASGFTFSTYGMHWVREAPGKGLEWLSYISGGSSYIFY ADSVRGRFTISRDNSENALYLQMNSLRAEDTAVYYCARILRGGSGMDLWGQGTLVTVSSA STKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSG LYSLSSVVEVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSC 1132 Heavy Chain (SEQ ID NO:282) EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSIGSYGGGTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARYVNFGMDYWGQGT LVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKT HTCPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKT ISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK Light Chain (SEQ ID NO:283) DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYGRNPPTFGQGTKLEIK RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC

Claims

1. A polypeptide having specificity for an antigen, said polypeptide comprising a heavy chain region and a light chain region, i. the polypeptide comprises one or more primary mutations to facilitate association of the heavy chain region with the light chain region, which mutations increase the predicted risk of inducing an immunogenic response and / or increase the immunogenicity of the polypeptide; ii. A polypeptide, wherein said polypeptide comprises one or more secondary mutations to reduce or avoid said predicted risk of inducing an immunogenic response and / or immunogenicity caused by said one or more primary mutations.

2. The polypeptide of claim 1, wherein the increase in immunogenicity is characterized as a higher predicted immunogenic risk compared to the predicted immunogenic risk of a primary mutation control polypeptide and / or a higher immunogenicity compared to the immunogenicity of a primary mutation control polypeptide, preferably wherein the primary mutation control polypeptide does not contain the one or more primary mutations.

3. 3. The polypeptide of claim 2, wherein the primary mutation control polypeptide comprises or consists of an amino acid sequence that is the same as the polypeptide before the one or more primary mutations are introduced.

4. 4. The polypeptide of claim 1, wherein the reduction in immunogenicity is characterized as a lower predicted immunogenicity risk compared to the predicted immunogenicity risk of a first secondary mutation control polypeptide and / or a lower immunogenicity compared to the immunogenicity of a first secondary mutation control polypeptide, preferably the first secondary mutation control polypeptide comprising the one or more primary mutations but not the one or more secondary mutations.

5. 5. The polypeptide of claim 4, wherein the first secondary mutation control polypeptide comprises or consists of an amino acid sequence that is the same as the polypeptide containing one or more of the primary mutations before the one or more secondary mutations are introduced.

6. 6. The polypeptide of any one of claims 1 to 5, wherein the avoidance of immunogenicity is characterized as a similar or the same predicted immunogenicity risk compared to the predicted immunogenicity risk of a second, secondary mutant control polypeptide, and / or a similar or the same immunogenicity compared to the immunogenicity of a second, secondary mutant control polypeptide, preferably wherein the second, secondary mutant control polypeptide does not comprise the one or more primary mutations or the one or more secondary mutations.

7. 7. The polypeptide of claim 6, wherein the second secondary mutation control polypeptide comprises or consists of an amino acid sequence that is the same as the polypeptide before the one or more primary mutations are introduced and before the one or more secondary mutations are introduced.

8. The polypeptide according to any one of claims 1 to 7, wherein the immunogenicity is antigen-presenting cell (APC)-dependent immunogenicity and / or T cell-dependent immunogenicity.

9. The polypeptide of any one of claims 1 to 8, wherein the secondary mutation reduces or prevents binding of the polypeptide to MHC class II and / or T cell receptor (TCR).

10. The polypeptide according to claim 8 or 9, wherein the APC is a dendritic cell.

11. 11. The polypeptide of any one of claims 1 to 10, wherein the heavy chain region comprises a CH1 domain and the primary mutation is at position 187 of the CH1 domain (according to the EU numbering system).

12. 12. The polypeptide of claim 11, wherein the primary mutation at position 187 of the CH1 domain is at position X of an amino acid sequence selected from Table D.

13. 13. The polypeptide of claim 11 or 12, wherein the primary mutation is T187E / D.

14. 14. The polypeptide of any one of claims 1 to 13, wherein the light chain region comprises a CKappa or CLambda domain and the primary mutation is at position 114 of the CKappa or CLambda domain (according to the EU or Kabat numbering system).

15. The polypeptide of any one of claims 1 to 14, wherein the primary mutation at position 114 of the CKappa or CLambda (preferably CKappa) domain is at position X of an amino acid sequence selected from Table B.

16. The polypeptide according to any one of claims 1 to 15, wherein the primary mutation is T / S114A.

17. 17. The polypeptide of any one of claims 1 to 16, wherein the heavy chain region comprises a CH1 domain and the secondary mutation is at position 180, 183, and / or 188 of the CH1 domain.

18. 18. The polypeptide of any one of claims 1 to 17, wherein the light chain region comprises a CKappa or Clambda (preferably CKappa) domain and the secondary mutation is at position 111 and / or 109 of the CKappa or Clambda (preferably CKappa) domain.

19. 19. The polypeptide of any one of claims 1 to 18, wherein the light chain region comprises a VL domain and the secondary mutation is at position 126 of the VL domain.

20. 20. The polypeptide of any one of claims 1 to 19, wherein the secondary mutations are at one or more (preferably two or more) of the following positions: position 180 of the CH1 domain, position 183 of the CH1 domain, position 188 of the CH1 domain, position 111 of the CKappa or CLambda (preferably CKappa) domain, position 109 of the CKappa or CLambda (preferably CKappa) domain, and position 126 of the VL domain.

21. The amino acid sequence selected from Table F, wherein the secondary mutation in the CH1 domain at position 180 is 180 and / or position 183 is X 183 and / or position 188 is X 188 The polypeptide according to any one of claims 1 to 20,

22. 22. The polypeptide of any one of claims 1 to 21, wherein the secondary mutation is Y180A, Y180G, Y180I, Y180N, Y180S, Y180T, Y180V, or Y180W, and / or S183N or S183T, and / or V188G.

23. The amino acid sequence selected from Table E, wherein the secondary mutation in the CKappa or CLambda domain at position 109 of the CKappa or CLambda domain is X 109 and / or said secondary mutation at position 111 of said CKappa or CLambda domain is at position X 111 The polypeptide according to any one of claims 1 to 22,

24. 24. The polypeptide of any one of claims 1 to 23, wherein the secondary mutation is A111R, A111T, A111W, or A111V, and / or T109P.

25. 25. The polypeptide of any one of claims 1 to 24, wherein the secondary mutation is I126A, I126G, I126H, I126N, I126P, I126Q, I126S, or I126T (according to the IMGT numbering system).

26. 26. The polypeptide of any one of claims 1 to 25, wherein the polypeptide comprises a heavy chain variable domain (VH) that comprises a Protein A binding site, and wherein the VH domain comprises a mutation that reduces or prevents binding of the Protein A to the Protein A binding site.

27. 27. The polypeptide of claim 26, wherein the mutation is at position 65 (according to the IMGT numbering system).

28. 28. The polypeptide of claim 26 or 27, wherein the mutation is T65E, T65A or T65I.

29. 1. A polypeptide having specificity for an antigen, said polypeptide comprising a heavy chain variable domain (VH) that comprises a Protein A binding site, said VH domain comprising a mutation that reduces or prevents binding of Protein A to said Protein A binding site.

30. 30. The polypeptide of claim 29, wherein the VH is derived from the IGHV3 germline gene family.

31. 31. The polypeptide of claim 29 or 30, wherein the mutation is at position 65 of the VH domain (according to the IMGT numbering system).

32. The polypeptide of any one of claims 29 to 31, wherein the mutation is T65E, T65A or T65I.

33. The method of any one of claims 1 to 32, wherein the polypeptide is a monospecific polypeptide.

34. 34. The polypeptide of claim 33, wherein the target antigen is an immunomodulator or a tumor cell associated antigen (TAA).

35. 35. The polypeptide of claim 34, wherein the immune modulator is a checkpoint molecule.

36. 36. The polypeptide of claim 35, wherein the checkpoint molecule is a stimulatory checkpoint molecule, such as CD40.

37. 35. The polypeptide of claim 34, wherein the TAA is 5T4, EpCAM, and / or CEACAM5.

38. The polypeptide of any one of claims 1 to 32, wherein the polypeptide is a bispecific polypeptide.

39. The polypeptide, (a) an immunoglobulin molecule having specificity for a first antigen, the immunoglobulin molecule comprising a first heavy chain region and a first light chain region; (b) at least one Fab fragment having specificity for a second antigen, the Fab fragment comprising a second heavy chain region and a second light chain region; the second light chain region is fused to the C-terminus of the first heavy chain region; 39. The polypeptide of claim 38, wherein the one or more primary mutations promote association of the first heavy chain region with the first light chain region and / or promote association of the second heavy chain region with the second light chain region.

40. 40. The polypeptide of claim 39, wherein the immunoglobulin molecule comprises two copies of the first heavy chain polypeptide and / or two copies of the first light chain polypeptide.

41. 41. The polypeptide of claim 39 or 40, wherein the antibody comprises two Fab fragments according to (b).

42. said immunoglobulin molecule comprising two copies of said first heavy chain polypeptide and two copies of said first light chain polypeptide; the bispecific antibody further comprises two Fab fragments according to (b), the first Fab fragment is fused to the C-terminus of a first copy of the first heavy chain polypeptide via the light chain polypeptide of the Fab fragment; 42. The polypeptide of any one of claims 39 to 41, wherein the second Fab fragment is fused to the C-terminus of a second copy of the first heavy chain polypeptide via the light chain polypeptide of the Fab fragment.

43. 43. The polypeptide of claim 42, wherein the first heavy chain region and / or the second heavy chain region comprises a CH1 domain, and the CH1 domain comprises the primary and secondary mutations.

44. 44. The polypeptide of claim 42 or 43, wherein the primary and secondary mutations are as defined in any one of claims 1 to 25.

45. 45. The polypeptide of any one of claims 42 to 44, wherein the first heavy chain region and / or the second heavy chain region, preferably the second heavy chain region, comprises a VH domain, wherein the VH domain comprises a Protein A binding site, and wherein the VH domain comprises a mutation that reduces or avoids binding of Protein A to the Protein A binding site.

46. 46. ​​The polypeptide of claim 45, wherein the mutation is as defined in claim 27 or 28.

47. A bispecific antibody, the bispecific antibody comprising: (a) an immunoglobulin molecule having specificity for a first antigen, the immunoglobulin molecule comprising two first heavy chain regions and two first light chain regions; (b) two Fab fragments having specificity for a second antigen, the Fab fragments comprising a second heavy chain region and a second light chain region; the second light chain region is fused to the C-terminus of the first heavy chain region; the polypeptide comprises one or more primary mutations to facilitate association of the heavy chain region with the light chain region, such mutations increasing the predicted risk of inducing an immunogenic response and / or increasing the immunogenicity of the polypeptide; A bispecific antibody, wherein said polypeptide comprises one or more secondary mutations to reduce or avoid said predicted risk of inducing an immunogenic response and / or immunogenicity caused by said one or more primary mutations.

48. 48. The polypeptide of claim 47, wherein the primary and secondary mutations are as defined in any one of claims 1 to 25.

49. A bispecific antibody, the bispecific antibody comprising: (a) an immunoglobulin molecule having specificity for a first antigen, the immunoglobulin molecule comprising two first heavy chain regions and two first light chain regions; (b) two Fab fragments having specificity for a second antigen, the Fab fragments comprising a second heavy chain region and a second light chain region; the second light chain region is fused to the C-terminus of the first heavy chain region; 1. A bispecific antibody, wherein the second heavy chain region comprises a VH domain, the VH domain comprising a Protein A binding site, and the VH domain comprises a mutation that reduces or avoids binding of Protein A to the Protein A binding site.

50. 50. The polypeptide of claim 49, wherein the mutation is as defined in claim 27 or 28.

51. A bispecific antibody, the bispecific antibody comprising: (a) an immunoglobulin molecule having specificity for a first antigen, the immunoglobulin molecule comprising two first heavy chain regions and two first light chain regions; (b) two Fab fragments having specificity for a second antigen, the Fab fragments comprising a second heavy chain region and a second light chain region; the second light chain region is fused to the C-terminus of the first heavy chain region; the polypeptide comprises one or more primary mutations to facilitate association of the heavy chain region with the light chain region, such mutations increasing the predicted risk of inducing an immunogenic response and / or increasing the immunogenicity of the polypeptide; said polypeptide comprises one or more secondary mutations to reduce or avoid said predicted risk of inducing an immunogenic response and / or immunogenicity caused by said one or more primary mutations, 1. A bispecific antibody, wherein the second heavy chain region comprises a VH domain, the VH domain comprising a Protein A binding site, and the VH domain comprises a mutation that reduces or abolishes binding of Protein A to the Protein A binding site.

52. 52. The polypeptide of claim 51, wherein the primary and secondary mutations are as defined in claims 1 to 25.

53. 53. The polypeptide of claim 51 or 52, wherein the mutation that reduces or abolishes binding of Protein A to the Protein A binding site is as defined in claim 26 or 27.

54. The polypeptide of any one of claims 39 to 53, wherein the first antigen and / or the second antigen is an immunomodulator.

55. 55. The polypeptide of claim 54, wherein the immune modulator is a checkpoint molecule.

56. 56. The polypeptide of claim 55, wherein the checkpoint molecule is a stimulatory checkpoint molecule, such as CD40.

57. The polypeptide of any one of claims 39 to 56, wherein the first antigen and / or the second antigen is a TAA.

58. 58. The polypeptide of claim 57, wherein the TAA is EpCAM, 5T4, or CEACAM5.

59. A composition comprising a polypeptide as defined in any one of claims 1 to 58 and at least one pharma- ceutically acceptable carrier.

60. A polypeptide as defined in any one of claims 1 to 58 or a composition as defined in claim 59 for use in medicine.

61. A polypeptide as defined in any one of claims 1 to 58 or a composition as defined in claim 59 for use in the treatment or prevention of cancer.

62. A method of treating an individual in need thereof, comprising administering to said individual a therapeutically effective amount of a polypeptide as defined in any one of claims 1 to 58 or a composition as defined in claim 59.

63. 60. A method of treating or preventing cancer in an individual in need thereof, comprising administering to said individual a therapeutically effective amount of a polypeptide as defined in any one of claims 1 to 58 or a composition as defined in claim 59.

64. 60. A polypeptide as defined in any one of claims 1 to 58 for use in the manufacture of a medicament for the treatment of an individual in need of treatment.

65. 60. A polypeptide as defined in any one of claims 1 to 58 for use in the manufacture of a medicament for the treatment or prevention of cancer.

66. Polypeptides and / or compositions and / or bispecific antibodies and / or methods and / or therapeutic methods and / or polypeptides for the uses described herein with reference to the descriptions and / or examples and / or figures.

Citation Information

Patent Citations

  • multispecific antigen binding protein

    JP2018516546A

  • Novel polypeptides

    WO2020127354A2